reference_id,authors,title,journal,year,volume,citation_footer,citation_type,citation,urls,pubmed_id,doi,header,reference_type,study_id,exclusion_reason,PUBMED_ID_TITLE_AUTHORS,PUBMED_ID_TITLE,PUBMED_ID_S2,N_CITATIONS,S2_PDF_LINK,CORE_PDF_LINK,PUBMED_ID
CD014383-bib-0001,"Borlido C, Remington G, Graff-Guerrero A, Arenovich T, Hazara M, Wang A, et al. ","Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized, double-blind, placebo-controlled study", Journal of Clinical Psychiatry ,2016,77,    ,['citation-journal']," Borlido C, Remington G, Graff-Guerrero A, Arenovich T, Hazara M, Wang A, et al. Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized, double-blind, placebo-controlled study.  Journal of Clinical Psychiatry 2016;77(1):e14-e20. CENTRAL [DOI: 10.4088/JCP.14m09321] [PMID: 26845273]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4088/JCP.14m09321', 'https://www.ncbi.nlm.nih.gov/pubmed/26845273', 'https://scholar.google.com/scholar_lookup?title=Switching+from+2+antipsychotics+to+1+antipsychotic+in+schizophrenia:+a+randomized,+double-blind,+placebo-controlled+study+&author=C+Borlido&author=G+Remington&author=A+Graff-Guerrero&author=T+Arenovich&author=M+Hazara&author=A+Wang&publication_year=2016&hl=en']",26845273,https://doi.org/10.4088/JCP.14m09321, Borlido 2016 {published data only (unpublished sought but not used)}  ,included,CD014383-bbs2-0001,,,,,,,,26845273
CD014383-bib-0002,NCT00493233. ,Antipsychotic polypharmacy in schizophrenia,,,,   ,['citation-other'], NCT00493233. Antipsychotic polypharmacy in schizophrenia. clinicaltrials.gov/ct2/show/NCT00493233 (first received 28 June 2007). CENTRAL    ,[''],,, Borlido 2016 {published data only (unpublished sought but not used)}  ,included,CD014383-bbs2-0001,,26845273,,,,,,26845273
CD014383-bib-0003,"Constantine RJ, Andel R, McPherson M, Tandon R. ",Is the risk of antipsychotic polypharmacy discontinuation dependent on the agents used?, Psychiatry Research ,2018,263,    ,['citation-journal']," Constantine RJ, Andel R, McPherson M, Tandon R. Is the risk of antipsychotic polypharmacy discontinuation dependent on the agents used? Psychiatry Research 2018;263:238-44. CENTRAL [DOI: 10.1016/j.psychres.2017.09.050]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.psychres.2017.09.050', 'https://www.ncbi.nlm.nih.gov/pubmed/29195836', 'https://scholar.google.com/scholar_lookup?title=Is+the+risk+of+antipsychotic+polypharmacy+discontinuation+dependent+on+the+agents+used?+&author=RJ+Constantine&author=R+Andel&author=M+McPherson&author=R+Tandon&publication_year=2018&hl=en']",29195836,https://doi.org/10.1016/j.psychres.2017.09.050, Constantine 2015 {published data only (unpublished sought but not used)}  ,included,CD014383-bbs2-0002,,,,,,,,29195836
CD014383-bib-0004,"Constantine RJ, Andel R, McPherson M, Tandon R. ",The risks and beneﬁts of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial, Schizophrenia Research ,2015,166,    ,['citation-journal']," Constantine RJ, Andel R, McPherson M, Tandon R. The risks and beneﬁts of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.  Schizophrenia Research 2015;166:194-200. CENTRAL [DOI: 10.1016/j.schres.2015.05.038] [PMID: 26141142]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.schres.2015.05.038', 'https://www.ncbi.nlm.nih.gov/pubmed/26141142', 'https://scholar.google.com/scholar_lookup?title=The+risks+and+beneﬁts+of+switching+patients+with+schizophrenia+or+schizoaffective+disorder+from+two+to+one+antipsychotic+medication:+a+randomized+controlled+trial+&author=RJ+Constantine&author=R+Andel&author=M+McPherson&author=R+Tandon&publication_year=2015&hl=en']",26141142,https://doi.org/10.1016/j.schres.2015.05.038, Constantine 2015 {published data only (unpublished sought but not used)}  ,included,CD014383-bbs2-0002,,29195836,,,,,,26141142
CD014383-bib-0005,"Essock SM, Schooler NR, Stroup ST, McEvoy JP, Rojas I, Jackson C, et al, The Schizophrenia Trials Network. ",Effectiveness of switching from antipsychotic polypharmacy to monotherapy, American Journal of Psychiatry ,2011,168,    ,['citation-journal']," Essock SM, Schooler NR, Stroup ST, McEvoy JP, Rojas I, Jackson C, et al, The Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy.  American Journal of Psychiatry 2011;168(7):702-8. CENTRAL [DOI: 10.1176/appi.ajp.2011.10060908] [PMID: 21536693]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1176/appi.ajp.2011.10060908', 'https://www.ncbi.nlm.nih.gov/pubmed/21536693', 'https://scholar.google.com/scholar_lookup?title=Effectiveness+of+switching+from+antipsychotic+polypharmacy+to+monotherapy&author=SM+Essock&author=NR+Schooler&author=ST+Stroup&author=JP+McEvoy&author=I+Rojas&author=C+Jackson&publication_year=2011&hl=en']",21536693,https://doi.org/10.1176/appi.ajp.2011.10060908, Essock 2011 {published and unpublished data}  ,included,CD014383-bbs2-0003,,,,,,,,21536693
CD014383-bib-0006,NCT00044655. ,Switching medication to treat schizophrenia,,,,   ,['citation-other'], NCT00044655. Switching medication to treat schizophrenia. clinicaltrials.gov/ct2/show/NCT00044655 (first received 5 September 2002). CENTRAL    ,[''],,, Essock 2011 {published and unpublished data}  ,included,CD014383-bbs2-0003,,22480442,,,,,,22480442
CD014383-bib-0007,"Hori H, Yoshimura R, Katsuki A, Sugita AI, Atake K, Nakamura J. ","Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients", Journal of Psychiatric Research ,2013,47,    ,['citation-journal']," Hori H, Yoshimura R, Katsuki A, Sugita AI, Atake K, Nakamura J. Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients.  Journal of Psychiatric Research 2013;47(12):1843-8. CENTRAL [DOI: 10.1016/j.jpsychires.2013.08.024] [PMID: 24054464]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.jpsychires.2013.08.024', 'https://www.ncbi.nlm.nih.gov/pubmed/24054464', 'https://scholar.google.com/scholar_lookup?title=Switching+to+antipsychotic+monotherapy+can+improve+attention+and+processing+speed,+and+social+activity+in+chronic+schizophrenia+patients+&author=H+Hori&author=R+Yoshimura&author=A+Katsuki&author=AI+Sugita&author=K+Atake&author=J+Nakamura&publication_year=2013&hl=en']",24054464,https://doi.org/10.1016/j.jpsychires.2013.08.024, Hori 2013 {published data only (unpublished sought but not used)}  ,included,CD014383-bbs2-0004,,24054464,24054464,24054464,42,,,24054464
CD014383-bib-0008,NCT00918021. ,Polypharmacy in clozapine-resistant schizophrenia,,,,   ,['citation-other'], NCT00918021. Polypharmacy in clozapine-resistant schizophrenia. clinicaltrials.gov/ct2/show/NCT00918021 (first received 11 June 2009). CENTRAL    ,[''],,, Repo‐Tiihonen 2012 {published data only (unpublished sought but not used)}  ,included,CD014383-bbs2-0005,,,,,,,,
CD014383-bib-0009,"Repo-Tiihonen E, Hallikainen T, Kivistö P, Tiihonen J. ",Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment, Mental Illness ,2012,4,    ,['citation-journal']," Repo-Tiihonen E, Hallikainen T, Kivistö P, Tiihonen J. Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment.  Mental Illness 2012;4(1):e1-e1. CENTRAL [DOI: 10.4081/mi.2012.e1] [PMID: 25478102]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4081/mi.2012.e1', 'https://www.ncbi.nlm.nih.gov/pubmed/25478102', 'https://scholar.google.com/scholar_lookup?title=Antipsychotic+polypharmacy+in+clozapine+resistant+schizophrenia:+a+randomized+controlled+trial+of+tapering+antipsychotic+co-treatment+&author=E+Repo-Tiihonen&author=T+Hallikainen&author=P+Kivistö&author=J+Tiihonen&publication_year=2012&hl=en']",25478102,https://doi.org/10.4081/mi.2012.e1, Repo‐Tiihonen 2012 {published data only (unpublished sought but not used)}  ,included,CD014383-bbs2-0005,,25478102,25478102,25478102,12,https://www.emerald.com/insight/content/doi/10.4081/mi.2012.e1/full/pdf?title=antipsychotic-polypharmacy-in-clozapine-resistant-schizophrenia-a-randomized-controlled-trial-of-tapering-antipsychotic-co-treatment,,25478102
CD014383-bib-0010,"Baandrup L, Allerup P, Lublin H, Nordentoft M, Peacock L, Glenthoj B. ",Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia out-patients, Acta Psychiatrica Scandinavica ,2010,122,    ,['citation-journal']," Baandrup L, Allerup P, Lublin H, Nordentoft M, Peacock L, Glenthoj B. Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia out-patients.  Acta Psychiatrica Scandinavica 2010;122(5):367-74. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/j.1600-0447.2010.01553.x', 'https://www.ncbi.nlm.nih.gov/pubmed/20456285', 'https://scholar.google.com/scholar_lookup?title=Evaluation+of+a+multifaceted+intervention+to+limit+excessive+antipsychotic+co-prescribing+in+schizophrenia+out-patients+&author=L+Baandrup&author=P+Allerup&author=H+Lublin&author=M+Nordentoft&author=L+Peacock&author=B+Glenthoj&publication_year=2010&hl=en']",20456285,https://doi.org/10.1111/j.1600-0447.2010.01553.x, Baandrup 2010 {published data only}  ,excluded,CD014383-bbs2-0006, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (educational intervention for practitioners) ,20456285,20456285,20456285,47,,,20456285
CD014383-bib-0011,NCT00541398. ,"Antipsychotic polypharmacy: prevalence, background and consequences",,,,   ,['citation-other']," NCT00541398. Antipsychotic polypharmacy: prevalence, background and consequences. clinicaltrials.gov/ct2/show/NCT00541398 (first received 10 October 2007). CENTRAL    ",[''],,, Baandrup 2010 {published data only}  ,excluded,CD014383-bbs2-0006, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (educational intervention for practitioners) ,,,,,,,
CD014383-bib-0012,"Corsini GU, DelZompo M, Cianchetti C, Mangoni A, Gessa GL. ",Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramine in parkinsonism, Psychopharmacology ,1976,47,    ,['citation-journal']," Corsini GU, DelZompo M, Cianchetti C, Mangoni A, Gessa GL. Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramine in parkinsonism.  Psychopharmacology 1976;47(2):169-73. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1007/BF00735817', 'https://scholar.google.com/scholar_lookup?title=Therapeutical+efficacy+of+a+combination+of+apomorphine+with+sulpiride+or+metoclopramine+in+parkinsonism+&author=GU+Corsini&author=M+DelZompo&author=C+Cianchetti&author=A+Mangoni&author=GL+Gessa&publication_year=1976&hl=en']",,https://doi.org/10.1007/BF00735817, Corsini 1976 {published data only}  ,excluded,CD014383-bbs2-0007, Design: not randomised ,,,1273213,9,,,1273213
CD014383-bib-0013,"DosReis S, Wu BS, Castillo WC, Tai MH. ",Heterogeneity among youth with serious mental illness in intensive care management and post-discharge polypharmacy use, Pharmacoepidemiology and Drug Safety ,2016,25,    ,['citation-journal']," DosReis S, Wu BS, Castillo WC, Tai MH. Heterogeneity among youth with serious mental illness in intensive care management and post-discharge polypharmacy use.  Pharmacoepidemiology and Drug Safety 2016;25:348. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Heterogeneity+among+youth+with+serious+mental+illness+in+intensive+care+management+and+post-discharge+polypharmacy+use+&author=S+DosReis&author=BS+Wu&author=WC+Castillo&author=MH+Tai&publication_year=2016&hl=en']",,, DosReis 2016 {published data only}  ,excluded,CD014383-bbs2-0008, Design: not randomised ,,,,,,,
CD014383-bib-0014,"Fricchione V, Balletta G, Addeo L, Manna G. ",Effectiveness of antipsychotic polypharmacy or monotherapy: real-world study outcomes,,,,   ,['citation-other']," Fricchione V, Balletta G, Addeo L, Manna G. Effectiveness of antipsychotic polypharmacy or monotherapy: real-world study outcomes. 25th ECNP Congress; 2012 Oct 13-17; Vienna, Austria. CENTRAL    ",[''],,, Fricchione 2012 {published data only}  ,excluded,CD014383-bbs2-0009, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction ,,,,,,,
CD014383-bib-0015,Chaplin R. ,Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia, Evidence-Based Mental Health ,2007,10,    ,['citation-journal'], Chaplin R. Risperidone improves symptoms in people who are hospitalised during an acute exacerbation of schizophrenia.  Evidence-Based Mental Health 2007;10(1):15. CENTRAL    Link to article     PubMed     Google Scholar     ,"['', 'https://doi.org/10.1136/ebmh.10.1.15', 'https://www.ncbi.nlm.nih.gov/pubmed/17255384', 'https://scholar.google.com/scholar_lookup?title=Risperidone+improves+symptoms+in+people+who+are+hospitalised+during+an+acute+exacerbation+of+schizophrenia+&author=R+Chaplin&publication_year=2007&hl=en']",17255384,https://doi.org/10.1136/ebmh.10.1.15, Greenspan 2004 {published data only}  ,excluded,CD014383-bbs2-0010," Design: randomised Participants: not stable schizophrenia (acute exacerbation, agitated) ",17255384,,17255384,1,,,17255384
CD014383-bib-0016,"Greenspan A, Kosik-Gonzalez C, Bossie C, Zhu Y, Gharabawi G. ",Predictors of readiness to discharge among inpatients with schizophrenia,,,,   ,['citation-other']," Greenspan A, Kosik-Gonzalez C, Bossie C, Zhu Y, Gharabawi G. Predictors of readiness to discharge among inpatients with schizophrenia. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York (NY). CENTRAL    ",[''],,, Greenspan 2004 {published data only}  ,excluded,CD014383-bbs2-0010," Design: randomised Participants: not stable schizophrenia (acute exacerbation, agitated) ",,,,,,,
CD014383-bib-0017,"Greenspan A, Kosik-Gonzalez C, Bossie C, Zhu Y, McLemore J, Gharabawi G. ",Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse,,,,   ,['citation-other']," Greenspan A, Kosik-Gonzalez C, Bossie C, Zhu Y, McLemore J, Gharabawi G. Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta (GA). CENTRAL    ",[''],,, Greenspan 2004 {published data only}  ,excluded,CD014383-bbs2-0010," Design: randomised Participants: not stable schizophrenia (acute exacerbation, agitated) ",,,,,,,
CD014383-bib-0018,"Greenspan A, Kosik-Gonzalez C, Moreau-Mallet V, Bossie CA, Rupnow MF, Zhu Y, et al. ",Risperidone vs quetiapine in inpatients with schizophrenia: a double-blind placebo-controlled study,,,,   ,['citation-other']," Greenspan A, Kosik-Gonzalez C, Moreau-Mallet V, Bossie CA, Rupnow MF, Zhu Y, et al. Risperidone vs quetiapine in inpatients with schizophrenia: a double-blind placebo-controlled study. 18th European College of Neuropsychopharmacology Congress; 2005 Oct 22-26; Amsterdam, the Netherlands. CENTRAL    ",[''],,, Greenspan 2004 {published data only}  ,excluded,CD014383-bbs2-0010," Design: randomised Participants: not stable schizophrenia (acute exacerbation, agitated) ",,,,,,,
CD014383-bib-0019,"Greenspan A, Kosik-Gonzalez C, Moreau-Mallet V, Bossie CA, Rupnow MF, Zhu Y, et al. ",Risperidone vs quetiapine in inpatients with schizophrenia: a double-blind placebo-controlled study, European Neuropsychopharmacology ,2005,15,    ,['citation-journal']," Greenspan A, Kosik-Gonzalez C, Moreau-Mallet V, Bossie CA, Rupnow MF, Zhu Y, et al. Risperidone vs quetiapine in inpatients with schizophrenia: a double-blind placebo-controlled study.  European Neuropsychopharmacology 2005;15(Suppl 3):S503. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Risperidone+vs+quetiapine+in+inpatients+with+schizophrenia:+a+double-blind+placebo-controlled+study+&author=A+Greenspan&author=C+Kosik-Gonzalez&author=V+Moreau-Mallet&author=CA+Bossie&author=MF+Rupnow&author=Y+Zhu&publication_year=2005&hl=en']",,, Greenspan 2004 {published data only}  ,excluded,CD014383-bbs2-0010," Design: randomised Participants: not stable schizophrenia (acute exacerbation, agitated) ",,,,,,,
CD014383-bib-0020,"Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF, et al. ","A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization", Schizophrenia Research ,2006,85,    ,['citation-journal']," Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.  Schizophrenia Research 2006;85(1-3):254-65. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.schres.2006.03.027', 'https://www.ncbi.nlm.nih.gov/pubmed/16797162', 'https://scholar.google.com/scholar_lookup?title=A+double-blind+comparison+of+risperidone,+quetiapine+and+placebo+in+patients+with+schizophrenia+experiencing+an+acute+exacerbation+requiring+hospitalization+&author=SG+Potkin&author=GM+Gharabawi&author=AJ+Greenspan&author=R+Mahmoud&author=C+Kosik-Gonzalez&author=MF+Rupnow&publication_year=2006&hl=en']",16797162,https://doi.org/10.1016/j.schres.2006.03.027, Greenspan 2004 {published data only}  ,excluded,CD014383-bbs2-0010," Design: randomised Participants: not stable schizophrenia (acute exacerbation, agitated) ",,16797162,16797162,87,,,16797162
CD014383-bib-0021,"Potkin SG, Greenspan A, Kosik-Gonzalez C, Bossie C, Rupnow M, Zhu Y, et al. ",A placebo-controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia, Schizophrenia Bulletin ,2005,31,    ,['citation-journal']," Potkin SG, Greenspan A, Kosik-Gonzalez C, Bossie C, Rupnow M, Zhu Y, et al. A placebo-controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia.  Schizophrenia Bulletin 2005;31:501. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=A+placebo-controlled+study+of+risperidone+vs+quetiapine+for+symptom+response+and+readiness+for+discharge+among+agitated+inpatients+with+schizophrenia+&author=SG+Potkin&author=A+Greenspan&author=C+Kosik-Gonzalez&author=C+Bossie&author=M+Rupnow&author=Y+Zhu&publication_year=2005&hl=en']",,, Greenspan 2004 {published data only}  ,excluded,CD014383-bbs2-0010," Design: randomised Participants: not stable schizophrenia (acute exacerbation, agitated) ",,,,,,,
CD014383-bib-0022,"Rupnow M, Greenspan A, Kosik-Gonzalez C, Bossie C, Zhu Y, Gharabawi G, et al. ","Polypharmacy in schizophrenia: data from a randomized, double-blind study",,,,   ,['citation-other']," Rupnow M, Greenspan A, Kosik-Gonzalez C, Bossie C, Zhu Y, Gharabawi G, et al. Polypharmacy in schizophrenia: data from a randomized, double-blind study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta (GA). CENTRAL    ",[''],,, Greenspan 2004 {published data only}  ,excluded,CD014383-bbs2-0010," Design: randomised Participants: not stable schizophrenia (acute exacerbation, agitated) ",,,,,,,
CD014383-bib-0023,"Rupnow MF, Greenspan A, Gharabawi GM, Kosik-Gonzalez C, Zhu Y, Stahl SM. ","Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder", Current Medical Research and Opinion ,2007,23,    ,['citation-journal']," Rupnow MF, Greenspan A, Gharabawi GM, Kosik-Gonzalez C, Zhu Y, Stahl SM. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder.  Current Medical Research and Opinion 2007;23(11):2815-22. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1185/030079907X233359', 'https://www.ncbi.nlm.nih.gov/pubmed/17910802', 'https://scholar.google.com/scholar_lookup?title=Incidence+and+costs+of+polypharmacy:+data+from+a+randomized,+double-blind,+placebo-controlled+study+of+risperidone+and+quetiapine+in+patients+with+schizophrenia+or+schizoaffective+disorder+&author=MF+Rupnow&author=A+Greenspan&author=GM+Gharabawi&author=C+Kosik-Gonzalez&author=Y+Zhu&author=SM+Stahl&publication_year=2007&hl=en']",17910802,https://doi.org/10.1185/030079907X233359, Greenspan 2004 {published data only}  ,excluded,CD014383-bbs2-0010," Design: randomised Participants: not stable schizophrenia (acute exacerbation, agitated) ",17910802,,17910802,35,,,17910802
CD014383-bib-0024,"Rupnow MF, Greenspan A, Kosik-Gonzalez C, Zhu Y, Gharabawi G, Stahl SM. ","Use and cost of polypharmacy in schizophrenia: data from a randomized, double-blind study of risperidone and quetiapine", Value in Health ,2005,8,    ,['citation-journal']," Rupnow MF, Greenspan A, Kosik-Gonzalez C, Zhu Y, Gharabawi G, Stahl SM. Use and cost of polypharmacy in schizophrenia: data from a randomized, double-blind study of risperidone and quetiapine.  Value in Health 2005;8(3):399. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S1098-3015(10)63082-3', 'https://scholar.google.com/scholar_lookup?title=Use+and+cost+of+polypharmacy+in+schizophrenia:+data+from+a+randomized,+double-blind+study+of+risperidone+and+quetiapine+&author=MF+Rupnow&author=A+Greenspan&author=C+Kosik-Gonzalez&author=Y+Zhu&author=G+Gharabawi&author=SM+Stahl&publication_year=2005&hl=en']",,https://doi.org/10.1016/S1098-3015(10)63082-3, Greenspan 2004 {published data only}  ,excluded,CD014383-bbs2-0010," Design: randomised Participants: not stable schizophrenia (acute exacerbation, agitated) ",17910802,,,7,https://doi.org/10.1016/s1098-3015(10)63082-3,,17910802
CD014383-bib-0025,"Rupnow MF, Stahl S, Greenspan A, Kosik-Gonzalez C, Gharabawi G. ","Use and cost of polypharmacy in schizophrenia: data from a randomized, double-blind study of risperidone and quetiapine", Schizophrenia Bulletin ,2005,31,    ,['citation-journal']," Rupnow MF, Stahl S, Greenspan A, Kosik-Gonzalez C, Gharabawi G. Use and cost of polypharmacy in schizophrenia: data from a randomized, double-blind study of risperidone and quetiapine.  Schizophrenia Bulletin 2005;31:550. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Use+and+cost+of+polypharmacy+in+schizophrenia:+data+from+a+randomized,+double-blind+study+of+risperidone+and+quetiapine+&author=MF+Rupnow&author=S+Stahl&author=A+Greenspan&author=C+Kosik-Gonzalez&author=G+Gharabawi&publication_year=2005&hl=en']",,, Greenspan 2004 {published data only}  ,excluded,CD014383-bbs2-0010," Design: randomised Participants: not stable schizophrenia (acute exacerbation, agitated) ",17910802,,,,,,17910802
CD014383-bib-0026,Honer W. ,A randomized controlled trial of antipsychotic polypharmacy: clozapine plus risperidone, European Neuropsychopharmacology ,2007,17,    ,['citation-journal'], Honer W. A randomized controlled trial of antipsychotic polypharmacy: clozapine plus risperidone.  European Neuropsychopharmacology 2007;17(Suppl 4):S200. CENTRAL    Link to article     Google Scholar     ,"['', 'https://doi.org/10.1016/S0924-977X(07)70237-7', 'https://scholar.google.com/scholar_lookup?title=A+randomized+controlled+trial+of+antipsychotic+polypharmacy:+clozapine+plus+risperidone&author=W+Honer&publication_year=2007&hl=en']",,https://doi.org/10.1016/S0924-977X(07)70237-7, Honer 2006 {published data only}  ,excluded,CD014383-bbs2-0011, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (dose augmentation) ,,,,3,,,
CD014383-bib-0027,"Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, et al. ",Clozapine alone versus clozapine and risperidone with refractory schizophrenia, New England Journal of Medicine ,2006,354,    ,['citation-journal']," Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia.  New England Journal of Medicine 2006;354(5):472-82. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1056/NEJMoa053222', 'https://www.ncbi.nlm.nih.gov/pubmed/16452559', 'https://scholar.google.com/scholar_lookup?title=Clozapine+alone+versus+clozapine+and+risperidone+with+refractory+schizophrenia&author=WG+Honer&author=AE+Thornton&author=EY+Chen&author=RC+Chan&author=JO+Wong&author=A+Bergmann&publication_year=2006&hl=en']",16452559,https://doi.org/10.1056/NEJMoa053222, Honer 2006 {published data only}  ,excluded,CD014383-bbs2-0011, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (dose augmentation) ,,,16452559,176,https://www.nejm.org/doi/pdf/10.1056/NEJMoa053222?articleTools=true,,16452559
CD014383-bib-0028,NCT00272584. ,International study of improving treatment for the most severely ill with schizophrenia,,,,   ,['citation-other'], NCT00272584. International study of improving treatment for the most severely ill with schizophrenia. clinicaltrials.gov/ct2/show/NCT00272584 (first received 6 January 2006). CENTRAL    ,[''],,, Honer 2006 {published data only}  ,excluded,CD014383-bbs2-0011, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (dose augmentation) ,,,,,,,
CD014383-bib-0029,"Lin CH, Kuo CC, Chou LS, Chen YH, Chen CC, Huang KH, et al. ","A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia", Journal of Clinical Psychopharmacology ,2010,30,    ,['citation-journal']," Lin CH, Kuo CC, Chou LS, Chen YH, Chen CC, Huang KH, et al. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia.  Journal of Clinical Psychopharmacology 2010;30(5):518-25. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/JCP.0b013e3181f28dff', 'https://www.ncbi.nlm.nih.gov/pubmed/20814315', 'https://scholar.google.com/scholar_lookup?title=A+randomized,+double-blind+comparison+of+risperidone+versus+low-dose+risperidone+plus+low-dose+haloperidol+in+treating+schizophrenia+&author=CH+Lin&author=CC+Kuo&author=LS+Chou&author=YH+Chen&author=CC+Chen&author=KH+Huang&publication_year=2010&hl=en']",20814315,https://doi.org/10.1097/JCP.0b013e3181f28dff, Lin 2010 {published data only}  ,excluded,CD014383-bbs2-0012, Design: randomised Population: not stable schizophrenia (acute exacerbation) ,,20814315,20814315,34,,,20814315
CD014383-bib-0030,"Lin CH, Kuo CC, Chou LS, Wang SJ, Chen MC, Chen CC. ","A randomized, double-blind, comparison of risperidone versus risperidone plus haloperidol treatment in schizophrenia", European Neuropsychopharmacology ,2009,19,    ,['citation-journal']," Lin CH, Kuo CC, Chou LS, Wang SJ, Chen MC, Chen CC. A randomized, double-blind, comparison of risperidone versus risperidone plus haloperidol treatment in schizophrenia.  European Neuropsychopharmacology 2009;19(Suppl 3):S256. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0924-977X(09)70369-4', 'https://scholar.google.com/scholar_lookup?title=A+randomized,+double-blind,+comparison+of+risperidone+versus+risperidone+plus+haloperidol+treatment+in+schizophrenia+&author=CH+Lin&author=CC+Kuo&author=LS+Chou&author=SJ+Wang&author=MC+Chen&author=CC+Chen&publication_year=2009&hl=en']",,https://doi.org/10.1016/S0924-977X(09)70369-4, Lin 2010 {published data only}  ,excluded,CD014383-bbs2-0012, Design: randomised Population: not stable schizophrenia (acute exacerbation) ,,,,1,,,
CD014383-bib-0031,"Lin CH, Wang FC, Huang YH, Lin SC, Kuo CC. ",Comparison of polypharmacy using low-dose second-generation antipsychotics plus low-dose first-generation antipsychotics with monotherapy using therapeutic-dose second-generation antipsychotics in schizophrenia – a pooled analysis, CNS Spectrums ,2019,24,    ,['citation-journal']," Lin CH, Wang FC, Huang YH, Lin SC, Kuo CC. Comparison of polypharmacy using low-dose second-generation antipsychotics plus low-dose first-generation antipsychotics with monotherapy using therapeutic-dose second-generation antipsychotics in schizophrenia – a pooled analysis.  CNS Spectrums 2019;24(6):632-3. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1017/S1092852919000877', 'https://www.ncbi.nlm.nih.gov/pubmed/31084636', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+polypharmacy+using+low-dose+second-generation+antipsychotics+plus+low-dose+first-generation+antipsychotics+with+monotherapy+using+therapeutic-dose+second-generation+antipsychotics+in+schizophrenia+–+a+pooled+analysis+&author=CH+Lin&author=FC+Wang&author=YH+Huang&author=SC+Lin&author=CC+Kuo&publication_year=2019&hl=en']",31084636,https://doi.org/10.1017/S1092852919000877, Lin 2010 {published data only}  ,excluded,CD014383-bbs2-0012, Design: randomised Population: not stable schizophrenia (acute exacerbation) ,31084636,31084636,31084636,1,,,31084636
CD014383-bib-0032,NCT00998608. ,Comparison of the efficacy and safety of risperidone versus risperidone plus low dose of haloperidol in the treatment of schizophrenia,,,,   ,['citation-other'], NCT00998608. Comparison of the efficacy and safety of risperidone versus risperidone plus low dose of haloperidol in the treatment of schizophrenia. clinicaltrials.gov/ct2/show/NCT00998608 (first received 20 October 2009). CENTRAL    ,[''],,, Lin 2010 {published data only}  ,excluded,CD014383-bbs2-0012, Design: randomised Population: not stable schizophrenia (acute exacerbation) ,,,,,,,
CD014383-bib-0033,"Lin CH, Wang FC, Huang YH, Lin SC, Kuo CC. ",Comparison of polypharmacy using low-dose second-generation antipsychotics plus low-dose first-generation antipsychotics with monotherapy using therapeutic-dose second-generation antipsychotics in schizophrenia – a pooled analysis, CNS Spectrums ,2019,24,    ,['citation-journal']," Lin CH, Wang FC, Huang YH, Lin SC, Kuo CC. Comparison of polypharmacy using low-dose second-generation antipsychotics plus low-dose first-generation antipsychotics with monotherapy using therapeutic-dose second-generation antipsychotics in schizophrenia – a pooled analysis.  CNS Spectrums 2019;24(6):632-3. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1017/S1092852919000877', 'https://www.ncbi.nlm.nih.gov/pubmed/31084636', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+polypharmacy+using+low-dose+second-generation+antipsychotics+plus+low-dose+first-generation+antipsychotics+with+monotherapy+using+therapeutic-dose+second-generation+antipsychotics+in+schizophrenia+–+a+pooled+analysis+&author=CH+Lin&author=FC+Wang&author=YH+Huang&author=SC+Lin&author=CC+Kuo&publication_year=2019&hl=en']",31084636,https://doi.org/10.1017/S1092852919000877, Lin 2013 {published data only}  ,excluded,CD014383-bbs2-0013, Design: randomised Population: not stable schizophrenia ,31084636,31084636,31084636,1,,,31084636
CD014383-bib-0034,"Lin CH, Wang FC, Lin SC, Huang YH, Chen CC, Lane HY. ","Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study", International Clinical Psychopharmacology ,2013,28,    ,['citation-journal']," Lin CH, Wang FC, Lin SC, Huang YH, Chen CC, Lane HY. Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.  International Clinical Psychopharmacology 2013;28(5):267-74. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/YIC.0b013e3283633a83', 'https://www.ncbi.nlm.nih.gov/pubmed/23778382', 'https://scholar.google.com/scholar_lookup?title=Antipsychotic+combination+using+low-dose+antipsychotics+is+as+efficacious+and+safe+as,+but+cheaper,+than+optimal-dose+monotherapy+in+the+treatment+of+schizophrenia:+a+randomized,+double-blind+study+&author=CH+Lin&author=FC+Wang&author=SC+Lin&author=YH+Huang&author=CC+Chen&author=HY+Lane&publication_year=2013&hl=en']",23778382,https://doi.org/10.1097/YIC.0b013e3283633a83, Lin 2013 {published data only}  ,excluded,CD014383-bbs2-0013, Design: randomised Population: not stable schizophrenia ,23778382,23778382,23778382,15,,,23778382
CD014383-bib-0035,NCT01615185. ,"A randomized, double-blind, comparison of the efficacy and safety of amisulpride versus low-dose amisulpride plus low-dose sulpiride in the treatment of schizophrenia",,,,   ,['citation-other']," NCT01615185. A randomized, double-blind, comparison of the efficacy and safety of amisulpride versus low-dose amisulpride plus low-dose sulpiride in the treatment of schizophrenia. clinicaltrials.gov/ct2/show/NCT01615185 (first received 8 June 2012). CENTRAL    ",[''],,, Lin 2013 {published data only}  ,excluded,CD014383-bbs2-0013, Design: randomised Population: not stable schizophrenia ,,,,,,,
CD014383-bib-0036,"Lin CH, Lin SC, Huang YH, Wang FC, Huang CJ. ",Early prediction of olanzapine-induced weight gain for schizophrenia patients, Psychiatry Research ,2018,263,    ,['citation-journal']," Lin CH, Lin SC, Huang YH, Wang FC, Huang CJ. Early prediction of olanzapine-induced weight gain for schizophrenia patients.  Psychiatry Research 2018;263:207-11. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.psychres.2018.02.058', 'https://www.ncbi.nlm.nih.gov/pubmed/29574355', 'https://scholar.google.com/scholar_lookup?title=Early+prediction+of+olanzapine-induced+weight+gain+for+schizophrenia+patients&author=CH+Lin&author=SC+Lin&author=YH+Huang&author=FC+Wang&author=CJ+Huang&publication_year=2018&hl=en']",29574355,https://doi.org/10.1016/j.psychres.2018.02.058, Lin 2017 {published data only}  ,excluded,CD014383-bbs2-0014, Design: randomised Population: not stable schizophrenia (acute exacerbation) ,,29574355,29574355,8,,,29574355
CD014383-bib-0037,"Lin CH, Wang FC, Huang YH, Lin SC, Kuo CC. ",Comparison of polypharmacy using low-dose second-generation antipsychotics plus low-dose first-generation antipsychotics with monotherapy using therapeutic-dose second-generation antipsychotics in schizophrenia – a pooled analysis, CNS Spectrums ,2019,24,    ,['citation-journal']," Lin CH, Wang FC, Huang YH, Lin SC, Kuo CC. Comparison of polypharmacy using low-dose second-generation antipsychotics plus low-dose first-generation antipsychotics with monotherapy using therapeutic-dose second-generation antipsychotics in schizophrenia – a pooled analysis.  CNS Spectrums 2019;24(6):632-3. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1017/S1092852919000877', 'https://www.ncbi.nlm.nih.gov/pubmed/31084636', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+polypharmacy+using+low-dose+second-generation+antipsychotics+plus+low-dose+first-generation+antipsychotics+with+monotherapy+using+therapeutic-dose+second-generation+antipsychotics+in+schizophrenia+–+a+pooled+analysis+&author=CH+Lin&author=FC+Wang&author=YH+Huang&author=SC+Lin&author=CC+Kuo&publication_year=2019&hl=en']",31084636,https://doi.org/10.1017/S1092852919000877, Lin 2017 {published data only}  ,excluded,CD014383-bbs2-0014, Design: randomised Population: not stable schizophrenia (acute exacerbation) ,31084636,31084636,31084636,1,,,31084636
CD014383-bib-0038,"Lin CH, Wang FC, Lin SC, Huang YH, Chen CC. ","A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia", Schizophrenia Research ,2017,185,    ,['citation-journal']," Lin CH, Wang FC, Lin SC, Huang YH, Chen CC. A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia.  Schizophrenia Research 2017;185:80-7. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.schres.2017.01.004', 'https://www.ncbi.nlm.nih.gov/pubmed/28109665', 'https://scholar.google.com/scholar_lookup?title=A+randomized,+double-blind,+comparison+of+the+efficacy+and+safety+of+low-dose+olanzapine+plus+low-dose+trifluoperazine+versus+full-dose+olanzapine+in+the+acute+treatment+of+schizophrenia+&author=CH+Lin&author=FC+Wang&author=SC+Lin&author=YH+Huang&author=CC+Chen&publication_year=2017&hl=en']",28109665,https://doi.org/10.1016/j.schres.2017.01.004, Lin 2017 {published data only}  ,excluded,CD014383-bbs2-0014, Design: randomised Population: not stable schizophrenia (acute exacerbation) ,28109665,28109665,28109665,12,,,28109665
CD014383-bib-0039,NCT02704962. ,Olanzapine vs. low-dose olanzapine plus trifluoperazine,,,,   ,['citation-other'], NCT02704962. Olanzapine vs. low-dose olanzapine plus trifluoperazine. clinicaltrials.gov/ct2/show/NCT02704962 (first received 10 March 2016). CENTRAL    ,[''],,, Lin 2017 {published data only}  ,excluded,CD014383-bbs2-0014, Design: randomised Population: not stable schizophrenia (acute exacerbation) ,,,,,,,
CD014383-bib-0040,NCT02676375. ,Nicotine receptor density and response to nicotine patch: Pt 2 extended treatment,,,,   ,['citation-other'], NCT02676375. Nicotine receptor density and response to nicotine patch: Pt 2 extended treatment. clinicaltrials.gov/ct2/show/NCT02676375 (first received 8 February 2016). CENTRAL    ,[''],,, NCT02676375 {published data only}  ,excluded,CD014383-bbs2-0015, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction ,,,,,,,
CD014383-bib-0041,"Alphs L, Nasrallah HA, Bossie CA, Fu DJ, Gopal S, Hough D, et al. ",Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy, International Clinical Psychopharmacology ,2016,31,    ,['citation-journal']," Alphs L, Nasrallah HA, Bossie CA, Fu DJ, Gopal S, Hough D, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy.  International Clinical Psychopharmacology 2016;31(4):202-9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/YIC.0000000000000125', 'https://www.ncbi.nlm.nih.gov/pubmed/26974214', 'https://scholar.google.com/scholar_lookup?title=Factors+associated+with+relapse+in+schizophrenia+despite+adherence+to+long-acting+injectable+antipsychotic+therapy+&author=L+Alphs&author=HA+Nasrallah&author=CA+Bossie&author=DJ+Fu&author=S+Gopal&author=D+Hough&publication_year=2016&hl=en']",26974214,https://doi.org/10.1097/YIC.0000000000000125, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,26974214,53,,,26974214
CD014383-bib-0042,"Bilder RM, Pandina G, Lasser R, Rodriguez S, Turkoz I, Prosser J, et al. ",Cognitive and functional improvement with long-acting risperidone treatment,,,,   ,['citation-other']," Bilder RM, Pandina G, Lasser R, Rodriguez S, Turkoz I, Prosser J, et al. Cognitive and functional improvement with long-acting risperidone treatment. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. CENTRAL    ",[''],,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0043,"Bossie C, Gharabawi G, Rodriguez SC, Dragotta K, Simpson GM. ",Remission of schizophrenia symptoms associated with functional improvement,,,,   ,['citation-other']," Bossie C, Gharabawi G, Rodriguez SC, Dragotta K, Simpson GM. Remission of schizophrenia symptoms associated with functional improvement. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. CENTRAL    ",[''],,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0044,"Gharabawi G, Bossie C, Bouhours P, Turkoz I, Gearhart N, Kujawa M. ","Insight in schizophrenia: results from a 12-month, double-blind study insight in schizophrenia: results from a 12 month double blind study",,,,   ,['citation-other']," Gharabawi G, Bossie C, Bouhours P, Turkoz I, Gearhart N, Kujawa M. Insight in schizophrenia: results from a 12-month, double-blind study insight in schizophrenia: results from a 12 month double blind study. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. CENTRAL    ",[''],,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0045,"Gharabawi G, Bossie C, Turkoz I, Bouhours P, Kujawa M. ","Does insight predict functioning and quality of life in schizophrenia? Results from a 12-month, double-blind study",,,,   ,['citation-other']," Gharabawi G, Bossie C, Turkoz I, Bouhours P, Kujawa M. Does insight predict functioning and quality of life in schizophrenia? Results from a 12-month, double-blind study. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. CENTRAL    ",[''],,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0046,"Gharabawi G, Bossie C, Turkoz I, Kujawa M, Mahmoud R, Simpson G. ",The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable, Journal of Nervous and Mental Disease ,2007,195,    ,['citation-journal']," Gharabawi G, Bossie C, Turkoz I, Kujawa M, Mahmoud R, Simpson G. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.  Journal of Nervous and Mental Disease 2007;195(12):976-82. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/NMD.0b013e31815c1982', 'https://www.ncbi.nlm.nih.gov/pubmed/18091190', 'https://scholar.google.com/scholar_lookup?title=The+impact+of+insight+on+functioning+in+patients+with+schizophrenia+or+schizoaffective+disorder+receiving+risperidone+long-acting+injectable+&author=G+Gharabawi&author=C+Bossie&author=I+Turkoz&author=M+Kujawa&author=R+Mahmoud&author=G+Simpson&publication_year=2007&hl=en']",18091190,https://doi.org/10.1097/NMD.0b013e31815c1982, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,18091190,,18091190,34,,,18091190
CD014383-bib-0047,"Gharabawi GM, Bossie CA, Bouhours P, Turkoz I, Kujawa M. ",Insight in schizophrenia: clinical correlates and relationship to functioning, European Neuropsychopharmacology ,2006,16,    ,['citation-journal']," Gharabawi GM, Bossie CA, Bouhours P, Turkoz I, Kujawa M. Insight in schizophrenia: clinical correlates and relationship to functioning.  European Neuropsychopharmacology 2006;16(Suppl 4):S390. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S0924-977X(06)70477-1', 'https://scholar.google.com/scholar_lookup?title=Insight+in+schizophrenia:+clinical+correlates+and+relationship+to+functioning&author=GM+Gharabawi&author=CA+Bossie&author=P+Bouhours&author=I+Turkoz&author=M+Kujawa&publication_year=2006&hl=en']",,https://doi.org/10.1016/S0924-977X(06)70477-1, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,1,,,
CD014383-bib-0048,"Gharabawi GM, Bossie CA, Zhu Y. ",New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol, American Journal of Psychiatry ,2006,163,    ,['citation-journal']," Gharabawi GM, Bossie CA, Zhu Y. New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol.  American Journal of Psychiatry 2006;163(5):938-9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1176/ajp.2006.163.5.938a', 'https://www.ncbi.nlm.nih.gov/pubmed/16648343', 'https://scholar.google.com/scholar_lookup?title=New-onset+tardive+dyskinesia+in+patients+with+first-episode+psychosis+receiving+risperidone+or+haloperidol+&author=GM+Gharabawi&author=CA+Bossie&author=Y+Zhu&publication_year=2006&hl=en']",16648343,https://doi.org/10.1176/ajp.2006.163.5.938a, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,16648343,,16648343,16,,,16648343
CD014383-bib-0049,"Harvey P, Pandina G, Bilder R, Rodriguez S, Turkoz I, Gharabawi G. ",Cognitive and functional improvement with long-acting risperidone treatment,,,,   ,['citation-other']," Harvey P, Pandina G, Bilder R, Rodriguez S, Turkoz I, Gharabawi G. Cognitive and functional improvement with long-acting risperidone treatment. 44th Annual Meeting of the American College of Neuro-Psychopharmacology; 2005 Dec 11-15; Waikoloa (HI). CENTRAL    ",[''],,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0050,"Kujawa M, Bossie C, Gharabawi G, Turkoz I, Prosser J, Simpson G. ",Factors associated with improved psychosocial functioning in patients with schizophrenia, Schizophrenia Bulletin ,2007,33,    ,['citation-journal']," Kujawa M, Bossie C, Gharabawi G, Turkoz I, Prosser J, Simpson G. Factors associated with improved psychosocial functioning in patients with schizophrenia.  Schizophrenia Bulletin 2007;33(2):438. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Factors+associated+with+improved+psychosocial+functioning+in+patients+with+schizophrenia&author=M+Kujawa&author=C+Bossie&author=G+Gharabawi&author=I+Turkoz&author=J+Prosser&author=G+Simpson&publication_year=2007&hl=en']",,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0051,"Kujawa M, Bossie C, Turkoz I, Simpson G, Gharabawi G. ",Remission of schizophrenia symptoms associated with functional improvement,,,,   ,['citation-other']," Kujawa M, Bossie C, Turkoz I, Simpson G, Gharabawi G. Remission of schizophrenia symptoms associated with functional improvement. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. CENTRAL    ",[''],,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0052,"Lasser R, Pandina G, Bilder R, Harvey P, Rodriguez S, Turkoz I, et al. ",Cognitive and functional improvement with long-acting risperidone treatment,,,,   ,['citation-other']," Lasser R, Pandina G, Bilder R, Harvey P, Rodriguez S, Turkoz I, et al. Cognitive and functional improvement with long-acting risperidone treatment. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta (GA). CENTRAL    ",[''],,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0053,"Lasser RA, Rodriguez SC, Turkoz I, Mahableshwarkar AR, Gharabawi GM, Simpson GM. ",Optimization of long-acting risperidone for maintenance therapy in schizophrenia, Schizophrenia Bulletin ,2005,31,    ,['citation-journal']," Lasser RA, Rodriguez SC, Turkoz I, Mahableshwarkar AR, Gharabawi GM, Simpson GM. Optimization of long-acting risperidone for maintenance therapy in schizophrenia.  Schizophrenia Bulletin 2005;31:492. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Optimization+of+long-acting+risperidone+for+maintenance+therapy+in+schizophrenia&author=RA+Lasser&author=SC+Rodriguez&author=I+Turkoz&author=AR+Mahableshwarkar&author=GM+Gharabawi&author=GM+Simpson&publication_year=2005&hl=en']",,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0054,"Locklear J, Lasser RA, Rodriguez SC, Turkoz I, Mahableshwarkar AR, Feifel D. ",Maintenance therapy with long-acting risperidone: functioning and quality of life in patients with schizophrenia or schizoaffective disorder, Schizophrenia Bulletin ,2005,31,    ,['citation-journal']," Locklear J, Lasser RA, Rodriguez SC, Turkoz I, Mahableshwarkar AR, Feifel D. Maintenance therapy with long-acting risperidone: functioning and quality of life in patients with schizophrenia or schizoaffective disorder.  Schizophrenia Bulletin 2005;31:494-5. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Maintenance+therapy+with+long-acting+risperidone:+functioning+and+quality+of+life+in+patients+with+schizophrenia+or+schizoaffective+disorder+&author=J+Locklear&author=RA+Lasser&author=SC+Rodriguez&author=I+Turkoz&author=AR+Mahableshwarkar&author=D+Feifel&publication_year=2005&hl=en']",,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0055,"MacFadden W, Bossie C, Turkoz I, Diekamp B, Ibach B, Haskins JT. ",Effect of long-acting injectable risperidone on clinical outcomes in recently diagnosed stable schizophrenia patients,,,,   ,['citation-other']," MacFadden W, Bossie C, Turkoz I, Diekamp B, Ibach B, Haskins JT. Effect of long-acting injectable risperidone on clinical outcomes in recently diagnosed stable schizophrenia patients. 26th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2008 Jul 13-17; Munich, Germany. CENTRAL    ",[''],,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0056,"MacFadden W, Bossie C, Turkoz I, Dorson P, Haskins T. ",Effect of long-acting injectable risperidone on clinical outcomes in stable schizophrenia patients with early illness,,,,   ,['citation-other']," MacFadden W, Bossie C, Turkoz I, Dorson P, Haskins T. Effect of long-acting injectable risperidone on clinical outcomes in stable schizophrenia patients with early illness. 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington (DC). CENTRAL    ",[''],,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0057,"MacFadden W, Bossie CA, Turkoz I, Haskins JT. ",Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia, International Clinical Psychopharmacology ,2010,25,    ,['citation-journal']," MacFadden W, Bossie CA, Turkoz I, Haskins JT. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia.  International Clinical Psychopharmacology 2010;25(2):75-82. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/YIC.0b013e3283347cbf', 'https://www.ncbi.nlm.nih.gov/pubmed/20101185', 'https://scholar.google.com/scholar_lookup?title=Risperidone+long-acting+therapy+in+stable+patients+with+recently+diagnosed+schizophrenia&author=W+MacFadden&author=CA+Bossie&author=I+Turkoz&author=JT+Haskins&publication_year=2010&hl=en']",20101185,https://doi.org/10.1097/YIC.0b013e3283347cbf, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,20101185,,20101185,20,,,20101185
CD014383-bib-0058,Mattys J. ,Improved cognition observed in patients with schizophrenia with risperidone long-acting injectable, European Neuropsychopharmacology ,2005,15,    ,['citation-journal'], Mattys J. Improved cognition observed in patients with schizophrenia with risperidone long-acting injectable.  European Neuropsychopharmacology 2005;15(Suppl 3):S497. CENTRAL    Google Scholar     ,"['', 'https://scholar.google.com/scholar_lookup?title=Improved+cognition+observed+in+patients+with+schizophrenia+with+risperidone+long-acting+injectable+&author=J+Mattys&publication_year=2005&hl=en']",,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0059,NCT00297388. ,"A 52-wk prospective, randomized, double-blind, multicenter study of relapse following transition from oral antipsychotic medication to 2 different doses (25 or 50 mg every 2 wks) of risperidone long-acting microspheres (Risperdal CONSTA) in adults with schizophrenia or schizoaffective disorder",,,,   ,['citation-other']," NCT00297388. A 52-wk prospective, randomized, double-blind, multicenter study of relapse following transition from oral antipsychotic medication to 2 different doses (25 or 50 mg every 2 wks) of risperidone long-acting microspheres (Risperdal CONSTA) in adults with schizophrenia or schizoaffective disorder. clinicaltrials.gov/ct2/show/NCT00297388 (first received 28 February 2006). CENTRAL    ",[''],,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,26974214,,,,,,26974214
CD014383-bib-0060,"Pandina G, Bilder R, Turkoz I, Alphs L. ","Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder", Schizophrenia Research ,2013,143,    ,['citation-journal']," Pandina G, Bilder R, Turkoz I, Alphs L. Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder.  Schizophrenia Research 2013;143(2-3):312-8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.schres.2012.11.031', 'https://www.ncbi.nlm.nih.gov/pubmed/23276482', 'https://scholar.google.com/scholar_lookup?title=Identification+of+clinically+meaningful+relationships+among+cognition,+functionality,+and+symptoms+in+subjects+with+schizophrenia+or+schizoaffective+disorder+&author=G+Pandina&author=R+Bilder&author=I+Turkoz&author=L+Alphs&publication_year=2013&hl=en']",23276482,https://doi.org/10.1016/j.schres.2012.11.031, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,23276482,,23276482,23,,,23276482
CD014383-bib-0061,"Pandina GJ, Gharabawi G, Rodriguez S, Lasser R. ",The relationship between cognitive measures and functional outcomes in schizophrenia,,,,   ,['citation-other']," Pandina GJ, Gharabawi G, Rodriguez S, Lasser R. The relationship between cognitive measures and functional outcomes in schizophrenia. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York (NY). CENTRAL    ",[''],,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0062,"Rodriguez SC, Kujawa M, Turkoz I, Rediess S, Gharabawi G. ",Long-acting risperidone treatment following antipsychotic polypharmacy,,,,   ,['citation-other']," Rodriguez SC, Kujawa M, Turkoz I, Rediess S, Gharabawi G. Long-acting risperidone treatment following antipsychotic polypharmacy. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. CENTRAL    ",[''],,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0063,"Rodriguez SC, Lasser R, Turkoz I, Mahableshwarkar AR, Gharabawi GM, Chung H, et al. ",Optimized long-acting risperidone maintenance therapy,,,,   ,['citation-other']," Rodriguez SC, Lasser R, Turkoz I, Mahableshwarkar AR, Gharabawi GM, Chung H, et al. Optimized long-acting risperidone maintenance therapy. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta (GA). CENTRAL    ",[''],,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0064,"Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, et al. ",A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder, Journal of Clinical Psychiatry ,2006,67,    ,['citation-journal']," Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.  Journal of Clinical Psychiatry 2006;67(8):1194-203. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4088/JCP.v67n0804', 'https://www.ncbi.nlm.nih.gov/pubmed/16965196', 'https://scholar.google.com/scholar_lookup?title=A+1-year+double-blind+study+of+2+doses+of+long-acting+risperidone+in+stable+patients+with+schizophrenia+or+schizoaffective+disorder+&author=GM+Simpson&author=RA+Mahmoud&author=RA+Lasser&author=M+Kujawa&author=CA+Bossie&author=I+Turkoz&publication_year=2006&hl=en']",16965196,https://doi.org/10.4088/JCP.v67n0804, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,16965196,92,,,16965196
CD014383-bib-0065,"Turkoz I, Lasser R, Rodriguez SC, Locklear JC, Mahableshwarkar AR, Gharabawi GM, et al. ",Functioning and quality of life during long-acting risperidone maintenance treatment,,,,   ,['citation-other']," Turkoz I, Lasser R, Rodriguez SC, Locklear JC, Mahableshwarkar AR, Gharabawi GM, et al. Functioning and quality of life during long-acting risperidone maintenance treatment. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta (GA). CENTRAL    ",[''],,, Simpson 2006 {published and unpublished data}  ,excluded,CD014383-bbs2-0016, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (comparison of different doses) ,,,,,,,
CD014383-bib-0066,"Stahl S, Rupnow M, Greenspan A, Kosik-Gonzalez C, Zhu Y, Gharabawi G. ","Use and cost of polypharmacy in schizophrenia: data from a randomized, double-blind study of risperidone and quetiapine", Neuropsychopharmacology ,2004,29,    ,['citation-journal']," Stahl S, Rupnow M, Greenspan A, Kosik-Gonzalez C, Zhu Y, Gharabawi G. Use and cost of polypharmacy in schizophrenia: data from a randomized, double-blind study of risperidone and quetiapine.  Neuropsychopharmacology 2004;29(Suppl 1):S227. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Use+and+cost+of+polypharmacy+in+schizophrenia:+data+from+a+randomized,+double-blind+study+of+risperidone+and+quetiapine+&author=S+Stahl&author=M+Rupnow&author=A+Greenspan&author=C+Kosik-Gonzalez&author=Y+Zhu&author=G+Gharabawi&publication_year=2004&hl=en']",,, Stahl 2004 {published data only}  ,excluded,CD014383-bbs2-0017, Design: randomised Population: not stable schizophrenia (acute exacerbation) ,17910802,,,,,,17910802
CD014383-bib-0067,"Sukegawa T, Ito T, Hasegawa M, Mizuno Y, Inagaki A, Sakamoto H, et al. ",A randomized controlled trial on the dose reduction and simplification for polypharmacy of antipsychotics, Tottori Journal of Clinical Research ,2008,1,    ,['citation-journal']," Sukegawa T, Ito T, Hasegawa M, Mizuno Y, Inagaki A, Sakamoto H, et al. A randomized controlled trial on the dose reduction and simplification for polypharmacy of antipsychotics.  Tottori Journal of Clinical Research 2008;1(1):169-81. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=A+randomized+controlled+trial+on+the+dose+reduction+and+simplification+for+polypharmacy+of+antipsychotics+&author=T+Sukegawa&author=T+Ito&author=M+Hasegawa&author=Y+Mizuno&author=A+Inagaki&author=H+Sakamoto&publication_year=2008&hl=en']",,, Sukegawa 2008 {published data only}  ,excluded,CD014383-bbs2-0018, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (combined dose reduction and polypharmacy reduction)  ,,,,,,,
CD014383-bib-0068,"Sumic JC, Baric V, Bilic P, Herceg M, Sisek-Sprem M, Jukic V. ",QTc and psychopharmacs: are there any differences between monotherapy and polytherapy, Annals of General Psychiatry ,2007,6,    ,['citation-journal']," Sumic JC, Baric V, Bilic P, Herceg M, Sisek-Sprem M, Jukic V. QTc and psychopharmacs: are there any differences between monotherapy and polytherapy.  Annals of General Psychiatry 2007;6:13. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/1744-859X-6-13', 'https://www.ncbi.nlm.nih.gov/pubmed/17477877', 'https://scholar.google.com/scholar_lookup?title=QTc+and+psychopharmacs:+are+there+any+differences+between+monotherapy+and+polytherapy&author=JC+Sumic&author=V+Baric&author=P+Bilic&author=M+Herceg&author=M+Sisek-Sprem&author=V+Jukic&publication_year=2007&hl=en']",17477877,https://doi.org/10.1186/1744-859X-6-13, Sumic 2007 {published data only}  ,excluded,CD014383-bbs2-0019, Design: not randomised ,17477877,17477877,17477877,22,https://annals-general-psychiatry.biomedcentral.com/track/pdf/10.1186/1744-859X-6-13,,17477877
CD014383-bib-0069,"Thompson A, Barley M, Sullivan SA, Strange SO, Moore L, Sipos A, et al. ",A pragmatic cluster randomised controlled trial of a complex ward-based intervention on antipsychotic polypharmacy prescribing in adult psychiatric inpatient wards,,,,   ,['citation-other']," Thompson A, Barley M, Sullivan SA, Strange SO, Moore L, Sipos A, et al. A pragmatic cluster randomised controlled trial of a complex ward-based intervention on antipsychotic polypharmacy prescribing in adult psychiatric inpatient wards. 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Jan 1; Davos, Switzerland. CENTRAL    ",[''],,, Thompson 2008 {published data only}  ,excluded,CD014383-bbs2-0020, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction ,,,,,,,
CD014383-bib-0070,"Thompson A, Sullivan SA, Barley M, Strange SO, Moore L, Rogers P, et al. ",The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards – a cluster randomized controlled trial, Psychological Medicine  ,2008,38,    ,['citation-journal']," Thompson A, Sullivan SA, Barley M, Strange SO, Moore L, Rogers P, et al. The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards – a cluster randomized controlled trial.  Psychological Medicine  2008;38(5):705-15. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1017/S003329170700147X', 'https://www.ncbi.nlm.nih.gov/pubmed/17825122', 'https://scholar.google.com/scholar_lookup?title=The+DEBIT+trial:+an+intervention+to+reduce+antipsychotic+polypharmacy+prescribing+in+adult+psychiatry+wards+–+a+cluster+randomized+controlled+trial+&author=A+Thompson&author=SA+Sullivan&author=M+Barley&author=SO+Strange&author=L+Moore&author=P+Rogers&publication_year=2008&hl=en']",17825122,https://doi.org/10.1017/S003329170700147X, Thompson 2008 {published data only}  ,excluded,CD014383-bbs2-0020, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction ,,17825122,17825122,70,https://orca.cardiff.ac.uk/id/eprint/19271/1/Thompson%202008.pdf,,17825122
CD014383-bib-0071,"Veraksa A, Egorov A. ",Pharmacotherapy of acute psychotic states: the reason for benzodiazepines and valproic acid augmentation, European Psychiatry ,2016,33,    ,['citation-journal']," Veraksa A, Egorov A. Pharmacotherapy of acute psychotic states: the reason for benzodiazepines and valproic acid augmentation.  European Psychiatry 2016;33:S612. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.eurpsy.2016.01.2287', 'https://scholar.google.com/scholar_lookup?title=Pharmacotherapy+of+acute+psychotic+states:+the+reason+for+benzodiazepines+and+valproic+acid+augmentation+&author=A+Veraksa&author=A+Egorov&publication_year=2016&hl=en']",,https://doi.org/10.1016/j.eurpsy.2016.01.2287, Veraksa 2016 {published data only}  ,excluded,CD014383-bbs2-0021," Design: randomised Population: not 80% schizophrenia, not stable schizophrenia ",,,,1,,,
CD014383-bib-0072,"Verdoorn S, Kwint HF, Blom JW, Gussekloo J, Bouvy ML. ","Effects of a clinical medication review focused on personal goals, quality of life, and health problems in older persons with polypharmacy: a randomised controlled trial (DREAMeR-study)", PLOS Medicine ,2019,16,    ,['citation-journal']," Verdoorn S, Kwint HF, Blom JW, Gussekloo J, Bouvy ML. Effects of a clinical medication review focused on personal goals, quality of life, and health problems in older persons with polypharmacy: a randomised controlled trial (DREAMeR-study).  PLOS Medicine 2019;16(5):e1002798. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1371/journal.pmed.1002798', 'https://www.ncbi.nlm.nih.gov/pubmed/31067214', 'https://scholar.google.com/scholar_lookup?title=Effects+of+a+clinical+medication+review+focused+on+personal+goals,+quality+of+life,+and+health+problems+in+older+persons+with+polypharmacy:+a+randomised+controlled+trial+(DREAMeR-study)+&author=S+Verdoorn&author=HF+Kwint&author=JW+Blom&author=J+Gussekloo&author=ML+Bouvy&publication_year=2019&hl=en']",31067214,https://doi.org/10.1371/journal.pmed.1002798, Verdoorn 2019 {published data only}  ,excluded,CD014383-bbs2-0022, Design: randomised Population: no schizophrenia  ,31067214,31067214,31067214,95,https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1002798&type=printable,,31067214
CD014383-bib-0073,"Sukegawa T, Inagaki A, Yamanouchi Y, Inada T, Yoshio T, Yoshimura R, et al. ",Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan, BMC Psychiatry ,2014,14,    ,['citation-journal']," Sukegawa T, Inagaki A, Yamanouchi Y, Inada T, Yoshio T, Yoshimura R, et al. Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan.  BMC Psychiatry 2014;14(1):103. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/1471-244X-14-103', 'https://www.ncbi.nlm.nih.gov/pubmed/24708857', 'https://scholar.google.com/scholar_lookup?title=Study+protocol:+safety+correction+of+high+dose+antipsychotic+polypharmacy+in+Japan&author=T+Sukegawa&author=A+Inagaki&author=Y+Yamanouchi&author=T+Inada&author=T+Yoshio&author=R+Yoshimura&publication_year=2014&hl=en']",24708857,https://doi.org/10.1186/1471-244X-14-103, Yamanouchi 2015 {published data only}  ,excluded,CD014383-bbs2-0023, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (combined dose reduction and polypharmacy reduction)  ,,24708857,24708857,18,https://bmcpsychiatry.biomedcentral.com/counter/pdf/10.1186/1471-244X-14-103,,24708857
CD014383-bib-0074,UMIN000004511. ,The clinical study to correct multiple and large amount of administering to antipsychotic safely and effectively,,,,   ,['citation-other'], UMIN000004511. The clinical study to correct multiple and large amount of administering to antipsychotic safely and effectively. center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005391 (first received 10 November 2010). CENTRAL    ,[''],,, Yamanouchi 2015 {published data only}  ,excluded,CD014383-bbs2-0023, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (combined dose reduction and polypharmacy reduction)  ,,,,,,,
CD014383-bib-0075,"Yamanouchi Y, Sukegawa T, Inagaki A, Inada T, Yoshio T, Yoshimura R, et al. ",Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method, International Journal of Neuropsychopharmacology ,2015,18,    ,['citation-journal']," Yamanouchi Y, Sukegawa T, Inagaki A, Inada T, Yoshio T, Yoshimura R, et al. Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method.  International Journal of Neuropsychopharmacology 2015;18:5. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1093/ijnp/pyu016', 'https://scholar.google.com/scholar_lookup?title=Evaluation+of+the+individual+safe+correction+of+antipsychotic+agent+polypharmacy+in+Japanese+patients+with+chronic+schizophrenia:+validation+of+safe+corrections+for+antipsychotic+polypharmacy+and+the+high-dose+method+&author=Y+Yamanouchi&author=T+Sukegawa&author=A+Inagaki&author=T+Inada&author=T+Yoshio&author=R+Yoshimura&publication_year=2015&hl=en']",,https://doi.org/10.1093/ijnp/pyu016, Yamanouchi 2015 {published data only}  ,excluded,CD014383-bbs2-0023, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (combined dose reduction and polypharmacy reduction)  ,,25522380,25522380,23,https://academic.oup.com/ijnp/article-pdf/18/5/pyu016/7692283/pyu016.pdf,,25522380
CD014383-bib-0076,"Yoon HW, Lee JS, Park SJ, Lee SK, Choi WJ, Kim TY. ",Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia, Clinical Neuropharmacology ,2016,39,    ,['citation-journal']," Yoon HW, Lee JS, Park SJ, Lee SK, Choi WJ, Kim TY. Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia.  Clinical Neuropharmacology 2016;39:288-94. CENTRAL [DOI: 10.1097/WNF.0000000000000175]    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/WNF.0000000000000175', 'https://www.ncbi.nlm.nih.gov/pubmed/27438182', 'https://scholar.google.com/scholar_lookup?title=Comparing+the+effectiveness+and+safety+of+the+addition+of+and+switching+to+aripiprazole+for+resolving+antipsychotic-induced+hyperprolactinemia+&author=HW+Yoon&author=JS+Lee&author=SJ+Park&author=SK+Lee&author=WJ+Choi&author=TY+Kim&publication_year=2016&hl=en']",27438182,https://doi.org/10.1097/WNF.0000000000000175, Yoon 2016 {published data only}  ,excluded,CD014383-bbs2-0024, Design: randomised Participants: people with stable schizophrenia Intervention: no polypharmacy reduction (switching to another antipsychotic) ,27438182,,27438182,31,,,27438182
CD014383-bib-0078,"Altman DG, Bland JM. ",Detecting skewness from summary information, BMJ ,1996,313,    ,['citation-journal']," Altman DG, Bland JM. Detecting skewness from summary information.  BMJ 1996;313(7066):1200. [DOI: 10.1136/bmj.313.7066.1200] [PMID: 8916759]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.313.7066.1200', 'https://www.ncbi.nlm.nih.gov/pubmed/8916759', 'https://scholar.google.com/scholar_lookup?title=Detecting+skewness+from+summary+information&author=DG+Altman&author=JM+Bland&publication_year=1996&hl=en']",8916759,https://doi.org/10.1136/bmj.313.7066.1200, Altman 1996 ,additional,CD014383-bbs2-0026,,8916759,,8916759,866,https://www.bmj.com/content/bmj/313/7066/1200.1.full.pdf,,8916759
CD014383-bib-0079,"Andreasen N, Carpenter W, Kane J, Lasser R, Marder S, Weinberger D. ",Remission in schizophrenia: proposed criteria and rationale for consensus, American Journal of Psychiatry ,2005,62,    ,['citation-journal']," Andreasen N, Carpenter W, Kane J, Lasser R, Marder S, Weinberger D. Remission in schizophrenia: proposed criteria and rationale for consensus.  American Journal of Psychiatry 2005;62:441-9. [DOI: 10.1176/appi.ajp.162.3.441] [PMID: 15741458]    Link to article     Google Scholar     ","['https://doi.org/10.1176/appi.ajp.162.3.441', 'https://scholar.google.com/scholar_lookup?title=Remission+in+schizophrenia:+proposed+criteria+and+rationale+for+consensus&author=N+Andreasen&author=W+Carpenter&author=J+Kane&author=R+Lasser&author=S+Marder&author=D+Weinberger&publication_year=2005&hl=en']",,https://doi.org/10.1176/appi.ajp.162.3.441, Andreasen 2005 ,additional,CD014383-bbs2-0027,,15741458,,15741458,2314,,,15741458
CD014383-bib-0080,"Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. ","Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study", American Journal of Psychiatry ,2013,170,    ,['citation-journal']," Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study.  American Journal of Psychiatry 2013;170:609-15. [DOI: 10.1176/appi.ajp.2013.12050674] [PMID: 23558429]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1176/appi.ajp.2013.12050674', 'https://www.ncbi.nlm.nih.gov/pubmed/23558429', 'https://scholar.google.com/scholar_lookup?title=Relapse+duration,+treatment+intensity,+and+brain+tissue+loss+in+schizophrenia:+a+prospective+longitudinal+MRI+study+&author=NC+Andreasen&author=D+Liu&author=S+Ziebell&author=A+Vora&author=BC+Ho&publication_year=2013&hl=en']",23558429,https://doi.org/10.1176/appi.ajp.2013.12050674, Andreasen 2013 ,additional,CD014383-bbs2-0028,,23558429,23558429,23558429,323,https://europepmc.org/articles/pmc3835590?pdf=render,,23558429
CD014383-bib-0081,APA 1987 American Psychiatric Association. ,,Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R),1987,,.   ,['citation-book']," APA 1987 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). Washington (DC): American Psychiatric Press, 1987.    ",[],,, APA 1987 ,additional,CD014383-bbs2-0029,,29369662,,,,,,29369662
CD014383-bib-0082,"Bighelli I, Ostuzzi G, Girlanda F, Cipriani A, Becker T, Koesters M, Barbui C. ",Implementation of treatment guidelines for specialist mental health care, Cochrane Database of Systematic Reviews ,2016,,    ,['citation-journal']," Bighelli I, Ostuzzi G, Girlanda F, Cipriani A, Becker T, Koesters M, Barbui C. Implementation of treatment guidelines for specialist mental health care.  Cochrane Database of Systematic Reviews 2016, Issue 12. Art. No: CD009780. [DOI: 10.1002/14651858.CD009780.pub3]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD009780.pub3', 'https://scholar.google.com/scholar_lookup?title=Implementation+of+treatment+guidelines+for+specialist+mental+health+care&author=I+Bighelli&author=G+Ostuzzi&author=F+Girlanda&author=A+Cipriani&author=T+Becker&author=M+Koesters&author=C+Barbui&publication_year=2016&hl=en']",,https://doi.org/10.1002/14651858.CD009780.pub3, Bighelli 2016 ,additional,CD014383-bbs2-0030,,27977851,,27977851,12,https://ora.ox.ac.uk/objects/uuid:71c759df-74b8-454f-9dbb-dcc27a4970b4/files/m910b524e9d187ad178acefbbcf95199a,,27977851
CD014383-bib-0083,"Bighelli I, Samara MT, Rodolico A, Hansen WP, Leucht S. ",Antipsychotic dose reduction compared to dose continuation for people with schizophrenia, Cochrane Database of Systematic Reviews ,2021,,    ,['citation-journal']," Bighelli I, Samara MT, Rodolico A, Hansen WP, Leucht S. Antipsychotic dose reduction compared to dose continuation for people with schizophrenia.  Cochrane Database of Systematic Reviews 2021, Issue 4. Art. No: CD014384. [DOI: 10.1002/14651858.CD014384]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Antipsychotic+dose+reduction+compared+to+dose+continuation+for+people+with+schizophrenia&author=I+Bighelli&author=MT+Samara&author=A+Rodolico&author=WP+Hansen&author=S+Leucht&publication_year=2021&hl=en'],,, Bighelli 2021a ,additional,CD014383-bbs2-0031,,36420692,,,,,,36420692
CD014383-bib-0084,Bland JM. ,Statistics notes. Trials randomised in clusters, BMJ ,1997,315,    ,['citation-journal'], Bland JM. Statistics notes. Trials randomised in clusters.  BMJ 1997;315(7108):600. [DOI: 10.1136/bmj.315.7108.600] [PMID: 9302962]    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1136/bmj.315.7108.600', 'https://www.ncbi.nlm.nih.gov/pubmed/9302962', 'https://scholar.google.com/scholar_lookup?title=Statistics+notes.+Trials+randomised+in+clusters&author=JM+Bland&publication_year=1997&hl=en']",9302962,https://doi.org/10.1136/bmj.315.7108.600, Bland 1997 ,additional,CD014383-bbs2-0032,,26037412,,9302962,548,https://www.bmj.com/content/bmj/315/7108/600.full.pdf,,9302962
CD014383-bib-0085,"Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. ",The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use, Therapie ,1999,54,    ,['citation-journal']," Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Aperçu sur la problématique des indices d'efficacité thérapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite].  Therapie 1999;54(4):405-11. [PMID: 10667106]    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/10667106', 'https://scholar.google.com/scholar_lookup?title=The+problem+of+therapeutic+efficacy+indices.+3.+Comparison+of+the+indices+and+their+use+&author=JP+Boissel&author=M+Cucherat&author=W+Li&author=G+Chatellier&author=F+Gueyffier&author=M+Buyse&publication_year=1999&hl=en']",10667106,, Boissel 1999 ,additional,CD014383-bbs2-0033,,,,,,,,10667106
CD014383-bib-0086,"Bouwmans C, de Sonneville C, Mulder CL, Hakkaart-van Roijen L. ",Employment and the associated impact on quality of life in people diagnosed with schizophrenia, Neuropsychiatric Disease and Treatment ,2015,11,    ,['citation-journal']," Bouwmans C, de Sonneville C, Mulder CL, Hakkaart-van Roijen L. Employment and the associated impact on quality of life in people diagnosed with schizophrenia.  Neuropsychiatric Disease and Treatment 2015;11:2125-42. [DOI: 10.2147/NDT.S83546] [PMID: 26316759]    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/26316759', 'https://scholar.google.com/scholar_lookup?title=Employment+and+the+associated+impact+on+quality+of+life+in+people+diagnosed+with+schizophrenia&author=C+Bouwmans&author=C+Sonneville&author=CL+Mulder&author=L+Hakkaart-vanRoijen&publication_year=2015&hl=en']",26316759,, Bouwmans 2015 ,additional,CD014383-bbs2-0034,,26316759,,,,,,26316759
CD014383-bib-0087,"Carpenter WT Jr, Buchanan RW. ",Schizophrenia, New England Journal of Medicine ,1994,330,    ,['citation-journal']," Carpenter WT Jr, Buchanan RW. Schizophrenia.  New England Journal of Medicine 1994;330:681-90. [DOI: 10.1056/NEJM199403103301006] [PMID: 8107719]    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/8107719', 'https://scholar.google.com/scholar_lookup?title=Schizophrenia&author=RW+Buchanan&publication_year=1994&hl=en']",8107719,, Carpenter 1994 ,additional,CD014383-bbs2-0035,,32332475,,,,,,8107719
CD014383-bib-0088,Deeks J. ,Issues in the selection for meta-analyses of binary data,,,,". 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa.   ",['citation-other']," Deeks J. Issues in the selection for meta-analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa.    ",[],,, Deeks 2000 ,additional,CD014383-bbs2-0036,,12111921,,,,,,12111921
CD014383-bib-0089,"Divine GW, Brown JT, Frazier LM. ",The unit of analysis error in studies about physicians' patient care behavior, Journal of General Internal Medicine ,1992,7,    ,['citation-journal']," Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior.  Journal of General Internal Medicine 1992;7(6):623-9. [DOI: 10.1007/BF02599201] [PMID: 1453246]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1007/BF02599201', 'https://www.ncbi.nlm.nih.gov/pubmed/1453246', ""https://scholar.google.com/scholar_lookup?title=The+unit+of+analysis+error+in+studies+about+physicians'+patient+care+behavior&author=GW+Divine&author=JT+Brown&author=LM+Frazier&publication_year=1992&hl=en""]",1453246,https://doi.org/10.1007/BF02599201, Divine 1992 ,additional,CD014383-bbs2-0037,,,,1453246,503,,,1453246
CD014383-bib-0090,"Donner A, Klar N. ",Issues in the meta-analysis of cluster randomized trials, Statistics in Medicine ,2002,21,    ,['citation-journal']," Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials.  Statistics in Medicine 2002;21(19):2971-80. [DOI: 10.1002/sim.1301] [PMID: 12325113]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/sim.1301', 'https://www.ncbi.nlm.nih.gov/pubmed/12325113', 'https://scholar.google.com/scholar_lookup?title=Issues+in+the+meta-analysis+of+cluster+randomized+trials&author=A+Donner&author=N+Klar&publication_year=2002&hl=en']",12325113,https://doi.org/10.1002/sim.1301, Donner 2002 ,additional,CD014383-bbs2-0038,,12325113,,12325113,606,,,12325113
CD014383-bib-0091,"Egger M, Davey Smith G, Schneider M, Minder C. ","Bias in meta-analysis detected by a simple, graphical test", BMJ ,1997,315,    ,['citation-journal']," Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test.  BMJ 1997;315(7109):629-34. [DOI: 10.1136/bmj.315.7109.629] [PMID: 9310563]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.315.7109.629', 'https://www.ncbi.nlm.nih.gov/pubmed/9310563', 'https://scholar.google.com/scholar_lookup?title=Bias+in+meta-analysis+detected+by+a+simple,+graphical+test&author=M+Egger&author=G+DaveySmith&author=M+Schneider&author=C+Minder&publication_year=1997&hl=en']",9310563,https://doi.org/10.1136/bmj.315.7109.629, Egger 1997 ,additional,CD014383-bbs2-0039,,9310563,,9310563,49922,https://europepmc.org/articles/pmc2127453?pdf=render,,9310563
CD014383-bib-0092,"Elbourne D, Altman DG, Higgins JP, Curtina F, Worthington HV, Vaile A. ",Meta-analyses involving cross-over trials: methodological issues, International Journal of Epidemiology ,2002,31,    ,['citation-journal']," Elbourne D, Altman DG, Higgins JP, Curtina F, Worthington HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues.  International Journal of Epidemiology 2002;31(1):140-9. [DOI: 10.1093/ije/31.1.140] [PMID: 11914310]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/ije/31.1.140', 'https://www.ncbi.nlm.nih.gov/pubmed/11914310', 'https://scholar.google.com/scholar_lookup?title=Meta-analyses+involving+cross-over+trials:+methodological+issues&author=D+Elbourne&author=DG+Altman&author=JP+Higgins&author=F+Curtina&author=HV+Worthington&author=A+Vaile&publication_year=2002&hl=en']",11914310,https://doi.org/10.1093/ije/31.1.140, Elbourne 2002 ,additional,CD014383-bbs2-0040,,,,11914310,1541,https://academic.oup.com/ije/article-pdf/31/1/140/18525000/310140.pdf,,11914310
CD014383-bib-0093,"Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, et al. ",Effectiveness of switching from antipsychotic polypharmacy to monotherapy, American Journal of Psychiatry ,2011,168,    ,['citation-journal']," Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy.  American Journal of Psychiatry 2011;168:702-8. [DOI: 10.1176/appi.ajp.2011.10060908] [PMID: 21536693]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1176/appi.ajp.2011.10060908', 'https://www.ncbi.nlm.nih.gov/pubmed/21536693', 'https://scholar.google.com/scholar_lookup?title=Effectiveness+of+switching+from+antipsychotic+polypharmacy+to+monotherapy&author=SM+Essock&author=NR+Schooler&author=TS+Stroup&author=JP+McEvoy&author=I+Rojas&author=C+Jackson&publication_year=2011&hl=en']",21536693,https://doi.org/10.1176/appi.ajp.2011.10060908, Essock 2011 ,additional,CD014383-bbs2-0041,,,,21536693,170,https://europepmc.org/articles/pmc3739691?pdf=render,,21536693
CD014383-bib-0094,"Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. ",Imputing missing standard deviations in meta-analyses can provide accurate results, Journal of Clinical Epidemiology ,2006,59,    ,['citation-journal']," Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results.  Journal of Clinical Epidemiology 2006;59(1):7-10. [DOI: 10.1016/j.jclinepi.2005.06.006] [PMID: 16360555]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.jclinepi.2005.06.006', 'https://www.ncbi.nlm.nih.gov/pubmed/16360555', 'https://scholar.google.com/scholar_lookup?title=Imputing+missing+standard+deviations+in+meta-analyses+can+provide+accurate+results&author=TA+Furukawa&author=C+Barbui&author=A+Cipriani&author=P+Brambilla&author=N+Watanabe&publication_year=2006&hl=en']",16360555,https://doi.org/10.1016/j.jclinepi.2005.06.006, Furukawa 2006 ,additional,CD014383-bbs2-0042,,16360555,,16360555,1339,,,16360555
CD014383-bib-0095,"Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. ",Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009, Schizophrenia Research ,2012,138,    ,['citation-journal']," Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.  Schizophrenia Research 2012;138:18-28. [DOI: 10.1016/j.schres.2012.03.018] [PMID: 22534420]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.schres.2012.03.018', 'https://www.ncbi.nlm.nih.gov/pubmed/22534420', 'https://scholar.google.com/scholar_lookup?title=Prevalence+and+correlates+of+antipsychotic+polypharmacy:+a+systematic+review+and+meta-regression+of+global+and+regional+trends+from+the+1970s+to+2009+&author=JA+Gallego&author=J+Bonetti&author=J+Zhang&author=JM+Kane&author=CU+Correll&publication_year=2012&hl=en']",22534420,https://doi.org/10.1016/j.schres.2012.03.018, Gallego 2012 ,additional,CD014383-bbs2-0043,,22534420,22534420,22534420,276,https://europepmc.org/articles/pmc3382997?pdf=render,,22534420
CD014383-bib-0096,"Galling B, Roldan A, Hagi K, Rietschel L, Walyzada F, Zheng W, et al. ","Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis", World Psychiatry ,2017,16,    ,['citation-journal']," Galling B, Roldan A, Hagi K, Rietschel L, Walyzada F, Zheng W, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.  World Psychiatry 2017;16:77-89. [DOI: 10.1002/wps.20387] [PMID: 28127934]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/wps.20387', 'https://www.ncbi.nlm.nih.gov/pubmed/28127934', 'https://scholar.google.com/scholar_lookup?title=Antipsychotic+augmentation+vs.+monotherapy+in+schizophrenia:+systematic+review,+meta-analysis+and+meta-regression+analysis+&author=B+Galling&author=A+Roldan&author=K+Hagi&author=L+Rietschel&author=F+Walyzada&author=W+Zheng&publication_year=2017&hl=en']",28127934,https://doi.org/10.1002/wps.20387, Galling 2017 ,additional,CD014383-bbs2-0044,,,28127934,28127934,208,https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/wps.20387,,28127934
CD014383-bib-0097,"Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. ",International consensus study of antipsychotic dosing, American Journal of Psychiatry ,2010,167,    ,['citation-journal']," Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing.  American Journal of Psychiatry 2010;167:686-93. [DOI: 10.1176/appi.ajp.2009.09060802] [PMID: 20360319]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1176/appi.ajp.2009.09060802', 'https://www.ncbi.nlm.nih.gov/pubmed/20360319', ""https://scholar.google.com/scholar_lookup?title=International+consensus+study+of+antipsychotic+dosing&author=DM+Gardner&author=AL+Murphy&author=H+O'Donnell&author=F+Centorrino&author=RJ+Baldessarini&publication_year=2010&hl=en""]",20360319,https://doi.org/10.1176/appi.ajp.2009.09060802, Gardner 2010 ,additional,CD014383-bbs2-0045,,20360319,,20360319,1270,,,20360319
CD014383-bib-0098,GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. ,"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017", Lancet ,2018,392,    ,['citation-journal']," GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.  Lancet 2018;392:1789-858. [DOI: 10.1016/S0140-6736(18)32279-7] [PMID: 30496104]    Link to article     PubMed     ","['https://doi.org/10.1016/S0140-6736(18)32279-7', 'https://www.ncbi.nlm.nih.gov/pubmed/30496104']",30496104,https://doi.org/10.1016/S0140-6736(18)32279-7, GBD 2018 ,additional,CD014383-bbs2-0046,,36240456,,30496104,7868,http://www.thelancet.com/article/S0140673618322797/pdf,,30496104
CD014383-bib-0099,,GRADEpro GDT,,2015,,. Available at gradepro.org.   ,['citation-other']," GRADEpro GDT. Version accessed 25 March 2022. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.    ",[],,, GRADEpro GDT [Computer program] ,additional,CD014383-bbs2-0047,,41626889,,,,,,41626889
CD014383-bib-0100,Gulliford MC. ,Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994, American Journal of Epidemiology ,1999,149,    ,['citation-journal'], Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.  American Journal of Epidemiology 1999;149(9):876-83. [DOI: 10.1093/oxfordjournals.aje.a009904] [PMID: 10221325]    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1093/oxfordjournals.aje.a009904', 'https://www.ncbi.nlm.nih.gov/pubmed/10221325', 'https://scholar.google.com/scholar_lookup?title=Components+of+variance+and+intraclass+correlations+for+the+design+of+community-based+surveys+and+intervention+studies:+data+from+the+Health+Survey+for+England+1994+&author=MC+Gulliford&publication_year=1999&hl=en']",10221325,https://doi.org/10.1093/oxfordjournals.aje.a009904, Gulliford 1999 ,additional,CD014383-bbs2-0048,,10221325,10221325,10221325,711,https://academic.oup.com/aje/article-pdf/149/9/876/264847/149-9-876.pdf,,10221325
CD014383-bib-0101,Guy W. ,,Clinical Global Impression Scale (CGI). ECDEU Assessment Manual for Psychopharmacology,1976,,.   ,['citation-book']," Guy W. Clinical Global Impression Scale (CGI). ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976.    ",[],,, Guy 1976 ,additional,CD014383-bbs2-0049,,41269369,,,,,,41269369
CD014383-bib-0102,"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. ",Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017, Pharmacopsychiatry ,2018,51,    ,['citation-journal']," Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017.  Pharmacopsychiatry 2018;51:9-62. [DOI: 10.1055/s-0043-116492] [PMID: 28910830]    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/28910830', 'https://scholar.google.com/scholar_lookup?title=Consensus+guidelines+for+therapeutic+drug+monitoring+in+neuropsychopharmacology:+update+2017+&author=C+Hiemke&author=N+Bergemann&author=HW+Clement&author=A+Conca&author=J+Deckert&author=K+Domschke&publication_year=2018&hl=en']",28910830,, Hiemke 2018 ,additional,CD014383-bbs2-0050,,,,,,,,28910830
CD014383-bib-0103,"Higgins JP, Thompson SG, Deeks JJ, Altman DG. ",Measuring inconsistency in meta-analyses, BMJ ,2003,327,    ,['citation-journal']," Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses.  BMJ 2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557] [PMID: 12958120]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.327.7414.557', 'https://www.ncbi.nlm.nih.gov/pubmed/12958120', 'https://scholar.google.com/scholar_lookup?title=Measuring+inconsistency+in+meta-analyses&author=JP+Higgins&author=SG+Thompson&author=JJ+Deeks&author=DG+Altman&publication_year=2003&hl=en']",12958120,https://doi.org/10.1136/bmj.327.7414.557, Higgins 2003 ,additional,CD014383-bbs2-0051,,12958120,,12958120,55390,https://europepmc.org/articles/pmc192859?pdf=render,,12958120
CD014383-bib-0104,"Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). ","Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021",,,,. Available from training.cochrane.org/handbook/archive/v6.2.   ,['citation-other']," Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.    ",[],,, Higgins 2021 ,additional,CD014383-bbs2-0052,,,,,,,,
CD014383-bib-0105,"Hjorthoj C, Sturup AE, McGrath JJ, Nordentoft M. ",Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis, Lancet Psychiatry ,2017,4,    ,['citation-journal']," Hjorthoj C, Sturup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis.  Lancet Psychiatry 2017;4(4):295-301. [DOI: 10.1016/S2215-0366(17)30078-0] [PMID: 28237639]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S2215-0366(17)30078-0', 'https://www.ncbi.nlm.nih.gov/pubmed/28237639', 'https://scholar.google.com/scholar_lookup?title=Years+of+potential+life+lost+and+life+expectancy+in+schizophrenia:+a+systematic+review+and+meta-analysis+&author=C+Hjorthoj&author=AE+Sturup&author=JJ+McGrath&author=M+Nordentoft&publication_year=2017&hl=en']",28237639,https://doi.org/10.1016/S2215-0366(17)30078-0, Hjorthoj 2017 ,additional,CD014383-bbs2-0053,,28237639,,28237639,1025,,,28237639
CD014383-bib-0106,"Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. ",Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia, Archives of General Psychiatry ,2011,68,    ,['citation-journal']," Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia.  Archives of General Psychiatry 2011;68:128-37. [DOI: 10.1001/archgenpsychiatry.2010.199] [PMID: 21300943]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archgenpsychiatry.2010.199', 'https://www.ncbi.nlm.nih.gov/pubmed/21300943', 'https://scholar.google.com/scholar_lookup?title=Long-term+antipsychotic+treatment+and+brain+volumes:+a+longitudinal+study+of+first-episode+schizophrenia+&author=BC+Ho&author=NC+Andreasen&author=S+Ziebell&author=R+Pierson&author=V+Magnotta&publication_year=2011&hl=en']",21300943,https://doi.org/10.1001/archgenpsychiatry.2010.199, Ho 2011 ,additional,CD014383-bbs2-0054,,21300943,,21300943,939,https://europepmc.org/articles/pmc3476840?pdf=render,,21300943
CD014383-bib-0107,Hutton JL. ,Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials, British Journal of Haematology ,2009,146,    ,['citation-journal'], Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials.  British Journal of Haematology 2009;146(1):27-30. [DOI: 10.1111/j.1365-2141.2009.07707.x] [PMID: 19438480]    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1111/j.1365-2141.2009.07707.x', 'https://www.ncbi.nlm.nih.gov/pubmed/19438480', 'https://scholar.google.com/scholar_lookup?title=Number+needed+to+treat+and+number+needed+to+harm+are+not+the+best+way+to+report+and+assess+the+results+of+randomised+clinical+trials+&author=JL+Hutton&publication_year=2009&hl=en']",19438480,https://doi.org/10.1111/j.1365-2141.2009.07707.x, Hutton 2009 ,additional,CD014383-bbs2-0055,,,,19438480,240,https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2141.2009.07707.x,,19438480
CD014383-bib-0108,"Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T. ",Brief Assessment of Cognition in Schizophrenia: validation of the Japanese version, Psychiatry and Clinical Neurosciences ,2007,61,    ,['citation-journal']," Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T. Brief Assessment of Cognition in Schizophrenia: validation of the Japanese version.  Psychiatry and Clinical Neurosciences 2007;61:602-9. [DOI: 10.1111/j.1440-1819.2007.01725.x]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/j.1440-1819.2007.01725.x', 'https://www.ncbi.nlm.nih.gov/pubmed/18081619', 'https://scholar.google.com/scholar_lookup?title=Brief+Assessment+of+Cognition+in+Schizophrenia:+validation+of+the+Japanese+version&author=Y+Kaneda&author=T+Sumiyoshi&author=R+Keefe&author=Y+Ishimoto&author=S+Numata&author=T+Ohmori&publication_year=2007&hl=en']",18081619,https://doi.org/10.1111/j.1440-1819.2007.01725.x, Kaneda 2007 ,additional,CD014383-bbs2-0056,,18081619,,18081619,246,https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1440-1819.2007.01725.x,,18081619
CD014383-bib-0109,"Kapur S, Zipursky R, Jones C, Remington G, Houle S. ","Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia", American Journal of Psychiatry ,2000,157,    ,['citation-journal']," Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.  American Journal of Psychiatry 2000;157:514-20. [DOI: 10.1176/appi.ajp.157.4.514] [PMID: 10739409]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1176/appi.ajp.157.4.514', 'https://www.ncbi.nlm.nih.gov/pubmed/10739409', 'https://scholar.google.com/scholar_lookup?title=Relationship+between+dopamine+D(2)+occupancy,+clinical+response,+and+side+effects:+a+double-blind+PET+study+of+first-episode+schizophrenia+&author=S+Kapur&author=R+Zipursky&author=C+Jones&author=G+Remington&author=S+Houle&publication_year=2000&hl=en']",10739409,https://doi.org/10.1176/appi.ajp.157.4.514, Kapur 2000 ,additional,CD014383-bbs2-0057,,10739409,10739409,10739409,1079,,,10739409
CD014383-bib-0110,"Kay SR, Opler LA, Fiszbein A. ",,Positive and Negative Syndrome Scale (PANSS) Manual,1986,,.   ,['citation-book']," Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi-Health Systems, 1986.    ",[],,, Kay 1986 ,additional,CD014383-bbs2-0058,,1935026,,,,,,1935026
CD014383-bib-0111,"Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editors(s). ",,Cochrane Handbook for Systematic Reviews of Interventions,2019,,    ,['citation-book']," Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editors(s). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley and Sons, 2019:67-107. [DOI: 10.1002/9781119536604.ch4]    Link to article     ",['https://doi.org/10.1002/9781119536604.ch4'],,https://doi.org/10.1002/9781119536604.ch4, Lefebvre 2019 ,additional,CD014383-bbs2-0059,,,,,407,https://methods.cochrane.org/sites/methods.cochrane.org.irmg/files/public/uploads/Annotatedbibliographtifyingunpublishedstudies.pdf,,
CD014383-bib-0112,"Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. ",Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology, Biological Psychiatry ,2006,59,    ,['citation-journal']," Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology.  Biological Psychiatry 2006;59(11):1001-5. [DOI: 10.1016/j.biopsych.2005.10.020] [PMID: 16503329]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.biopsych.2005.10.020', 'https://www.ncbi.nlm.nih.gov/pubmed/16503329', 'https://scholar.google.com/scholar_lookup?title=Attrition+in+randomized+controlled+clinical+trials:+methodological+issues+in+psychopharmacology&author=AC+Leon&author=CH+Mallinckrodt&author=C+Chuang-Stein&author=DG+Archibald&author=GE+Archer&author=K+Chartier&publication_year=2006&hl=en']",16503329,https://doi.org/10.1016/j.biopsych.2005.10.020, Leon 2006 ,additional,CD014383-bbs2-0060,,16503329,16503329,16503329,272,,,16503329
CD014383-bib-0113,"Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. ",Clinical implications of Brief Psychiatric Rating Scale scores, British Journal of Psychiatry ,2005,187,    ,['citation-journal']," Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores.  British Journal of Psychiatry 2005;187:366-71. [DOI: 10.1192/bjp.187.4.366] [PMID: 16199797]    Link to article     Google Scholar     ","['https://doi.org/10.1192/bjp.187.4.366', 'https://scholar.google.com/scholar_lookup?title=Clinical+implications+of+Brief+Psychiatric+Rating+Scale+scores&author=S+Leucht&author=JM+Kane&author=W+Kissling&author=J+Hamann&author=E+Etschel&author=R+Engel&publication_year=2005&hl=en']",,https://doi.org/10.1192/bjp.187.4.366, Leucht 2005a ,additional,CD014383-bbs2-0061,,16823384,,16199797,799,https://www.cambridge.org/core/services/aop-cambridge-core/content/view/94B18AC4BF64EE393D64479889623D30/S0007125000168084a.pdf/div-class-title-clinical-implications-of-brief-psychiatric-rating-scale-scores-div.pdf,,16199797
CD014383-bib-0114,"Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. ",What does the PANSS mean?, Schizophrenia Research ,2005,79,    ,['citation-journal']," Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophrenia Research 2005;79(2-3):231-8. [DOI: 10.1016/j.schres.2005.04.008] [PMID: 15982856]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.schres.2005.04.008', 'https://www.ncbi.nlm.nih.gov/pubmed/15982856', 'https://scholar.google.com/scholar_lookup?title=What+does+the+PANSS+mean?&author=S+Leucht&author=JM+Kane&author=W+Kissling&author=J+Hamann&author=E+Etschel&author=RR+Engel&publication_year=2005&hl=en']",15982856,https://doi.org/10.1016/j.schres.2005.04.008, Leucht 2005b ,additional,CD014383-bbs2-0062,,16823384,,15982856,1139,,,15982856
CD014383-bib-0115,"Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. ",Maintenance treatment with antipsychotic drugs for schizophrenia, Cochrane Database of Systematic Reviews ,2012,,    ,['citation-journal']," Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia.  Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No: CD008016. [DOI: 10.1002/14651858.CD008016.pub2]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD008016.pub2', 'https://scholar.google.com/scholar_lookup?title=Maintenance+treatment+with+antipsychotic+drugs+for+schizophrenia&author=S+Leucht&author=M+Tardy&author=K+Komossa&author=S+Heres&author=W+Kissling&author=JM+Davis&publication_year=2012&hl=en']",,https://doi.org/10.1002/14651858.CD008016.pub2, Leucht 2012 ,additional,CD014383-bbs2-0063,,32840872,,22592725,343,https://figshare.com/articles/journal_contribution/Maintenance_treatment_with_antipsychotic_drugs_for_schizophrenia/10757315/1/files/19268951.pdf,,22592725
CD014383-bib-0116,"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. ",Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis, Lancet ,2013,382,    ,['citation-journal']," Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.  Lancet 2013;382:951-62. [DOI: 10.1016/S0140-6736(13)60733-3] [PMID: 23810019]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(13)60733-3', 'https://www.ncbi.nlm.nih.gov/pubmed/23810019', 'https://scholar.google.com/scholar_lookup?title=Comparative+efficacy+and+tolerability+of+15+antipsychotic+drugs+in+schizophrenia:+a+multiple-treatments+meta-analysis+&author=S+Leucht&author=A+Cipriani&author=L+Spineli&author=D+Mavridis&author=D+Orey&author=F+Richter&publication_year=2013&hl=en']",23810019,https://doi.org/10.1016/S0140-6736(13)60733-3, Leucht 2013 ,additional,CD014383-bbs2-0064,,,,23810019,2222,,,23810019
CD014383-bib-0117,"Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, et al. ","Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors", American Journal of Psychiatry ,2017,174,    ,['citation-journal']," Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors.  American Journal of Psychiatry 2017;174(10):927-42. [DOI: 10.1176/appi.ajp.2017.16121358] [PMID: 28541090]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1176/appi.ajp.2017.16121358', 'https://www.ncbi.nlm.nih.gov/pubmed/28541090', 'https://scholar.google.com/scholar_lookup?title=Sixty+years+of+placebo-controlled+antipsychotic+drug+trials+in+acute+schizophrenia:+systematic+review,+Bayesian+meta-analysis,+and+meta-regression+of+efficacy+predictors+&author=S+Leucht&author=C+Leucht&author=M+Huhn&author=A+Chaimani&author=D+Mavridis&author=B+Helfer&publication_year=2017&hl=en']",28541090,https://doi.org/10.1176/appi.ajp.2017.16121358, Leucht 2017 ,additional,CD014383-bbs2-0065,,,28541090,,,,,28541090
CD014383-bib-0118,"Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. ",Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia, British Journal of Psychiatry ,2000,176,    ,['citation-journal']," Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia.  British Journal of Psychiatry 2000;176:249-52. [DOI: 10.1192/bjp.176.3.249] [PMID: 10755072]    Link to article     Google Scholar     ","['https://doi.org/10.1192/bjp.176.3.249', 'https://scholar.google.com/scholar_lookup?title=Unpublished+rating+scales:+a+major+source+of+bias+in+randomised+controlled+trials+of+treatments+for+schizophrenia+&author=M+Marshall&author=A+Lockwood&author=C+Bradley&author=C+Adams&author=C+Joy&author=M+Fenton&publication_year=2000&hl=en']",,https://doi.org/10.1192/bjp.176.3.249, Marshall 2000 ,additional,CD014383-bbs2-0066,,,,10755072,694,https://www.cambridge.org/core/services/aop-cambridge-core/content/view/B7234A75D107190562603C61F2487521/S0007125000264374a.pdf/div-class-title-unpublished-rating-scales-a-major-source-of-bias-in-randomised-controlled-trials-of-treatments-for-schizophrenia-div.pdf,,10755072
CD014383-bib-0119,"Matsui K, Tokumasu T, Takekita Y, Inada K, Kanazawa T, Kishimoto T, et al. ",Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: a systematic review and meta-analysis, Schizophrenia Research ,2019,209,    ,['citation-journal']," Matsui K, Tokumasu T, Takekita Y, Inada K, Kanazawa T, Kishimoto T, et al. Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: a systematic review and meta-analysis.  Schizophrenia Research 2019;209:50-7. [DOI: 10.1016/j.schres.2019.05.030]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.schres.2019.05.030', 'https://www.ncbi.nlm.nih.gov/pubmed/31182319', 'https://scholar.google.com/scholar_lookup?title=Switching+to+antipsychotic+monotherapy+vs.+staying+on+antipsychotic+polypharmacy+in+schizophrenia:+a+systematic+review+and+meta-analysis+&author=K+Matsui&author=T+Tokumasu&author=Y+Takekita&author=K+Inada&author=T+Kanazawa&author=T+Kishimoto&publication_year=2019&hl=en']",31182319,https://doi.org/10.1016/j.schres.2019.05.030, Matsui 2019 ,additional,CD014383-bbs2-0067,,,31182319,31182319,32,,,31182319
CD014383-bib-0120,"McGrath J, Saha S, Chant D, Welham J. ","Schizophrenia: a concise overview of incidence, prevalence, and mortality", Epidemiological Reviews ,2008,30,    ,['citation-journal']," McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality.  Epidemiological Reviews 2008;30:67-76. [DOI: 10.1093/epirev/mxn001] [PMID: 18480098]    Link to article     Google Scholar     ","['https://doi.org/10.1093/epirev/mxn001', 'https://scholar.google.com/scholar_lookup?title=Schizophrenia:+a+concise+overview+of+incidence,+prevalence,+and+mortality&author=J+McGrath&author=S+Saha&author=D+Chant&author=J+Welham&publication_year=2008&hl=en']",,https://doi.org/10.1093/epirev/mxn001, McGrath 2008 ,additional,CD014383-bbs2-0068,,18480098,18480098,18480098,2165,https://academic.oup.com/epirev/article-pdf/30/1/67/1717948/mxn001.pdf,,18480098
CD014383-bib-0121,"Misawa F, Shimizu K, Fujii Y, Miyata R, Koshiishi F, Kobayashi M, et al. ",Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for life-style effects? A cross-sectional study, BMC Psychiatry ,2011,11,    ,['citation-journal']," Misawa F, Shimizu K, Fujii Y, Miyata R, Koshiishi F, Kobayashi M, et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for life-style effects? A cross-sectional study.  BMC Psychiatry 2011;11:118. [DOI: 10.1186/1471-244X-11-118] [PMID: 21791046]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/1471-244X-11-118', 'https://www.ncbi.nlm.nih.gov/pubmed/21791046', 'https://scholar.google.com/scholar_lookup?title=Is+antipsychotic+polypharmacy+associated+with+metabolic+syndrome+even+after+adjustment+for+life-style+effects?+A+cross-sectional+study+&author=F+Misawa&author=K+Shimizu&author=Y+Fujii&author=R+Miyata&author=F+Koshiishi&author=M+Kobayashi&publication_year=2011&hl=en']",21791046,https://doi.org/10.1186/1471-244X-11-118, Misawa 2011 ,additional,CD014383-bbs2-0069,,,,21791046,91,https://bmcpsychiatry.biomedcentral.com/counter/pdf/10.1186/1471-244X-11-118,,21791046
CD014383-bib-0122,"Moreno-Küstner B, Martín C, Pastor L. ",Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses, PLOS One ,2018,13,    ,['citation-journal']," Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses.  PLOS One 2018;13:e0195687. [DOI: 10.1371/journal.pone.0195687] [PMID: 29649252]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1371/journal.pone.0195687', 'https://www.ncbi.nlm.nih.gov/pubmed/29649252', 'https://scholar.google.com/scholar_lookup?title=Prevalence+of+psychotic+disorders+and+its+association+with+methodological+issues.+A+systematic+review+and+meta-analyses+&author=B+Moreno-Küstner&author=C+Martín&author=L+Pastor&publication_year=2018&hl=en']",29649252,https://doi.org/10.1371/journal.pone.0195687, Moreno‐Küstner 2018 ,additional,CD014383-bbs2-0070,,29649252,,29649252,424,https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0195687&type=printable,,29649252
CD014383-bib-0123,"Overall JE, Gorham DR. ",The Brief Psychiatric Rating Scale, Psychological Reports ,1962,10,    ,['citation-journal']," Overall JE, Gorham DR. The Brief Psychiatric Rating Scale.  Psychological Reports 1962;10:799-812.    Link to article     Google Scholar     ","['https://doi.org/10.2466/pr0.1962.10.3.799', 'https://scholar.google.com/scholar_lookup?title=The+Brief+Psychiatric+Rating+Scale&author=JE+Overall&author=DR+Gorham&publication_year=1962&hl=en']",,https://doi.org/10.2466/pr0.1962.10.3.799, Overall 1962 ,additional,CD014383-bbs2-0071,,,,,11325,,,
CD014383-bib-0124,"Palmer BA, Pankratz VS, Bostwick J. ",The lifetime risk of suicide in schizophrenia: a reexamination, Archives of General Psychiatry ,2005,62,    ,['citation-journal']," Palmer BA, Pankratz VS, Bostwick J. The lifetime risk of suicide in schizophrenia: a reexamination.  Archives of General Psychiatry 2005;62:247-53. [DOI: 10.1001/archpsyc.62.3.247] [PMID: 15753237]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archpsyc.62.3.247', 'https://www.ncbi.nlm.nih.gov/pubmed/15753237', 'https://scholar.google.com/scholar_lookup?title=The+lifetime+risk+of+suicide+in+schizophrenia:+a+reexamination&author=BA+Palmer&author=VS+Pankratz&author=J+Bostwick&publication_year=2005&hl=en']",15753237,https://doi.org/10.1001/archpsyc.62.3.247, Palmer 2005 ,additional,CD014383-bbs2-0072,,15753237,,15753237,1030,,,15753237
CD014383-bib-0125,"Patel MX, Bishara D, Jayakumar S, Zalewska K, Shiers D, Crawford MJ, et al. ",Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales, European Neuropsychopharmacology ,2014,24,    ,['citation-journal']," Patel MX, Bishara D, Jayakumar S, Zalewska K, Shiers D, Crawford MJ, et al. Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales.  European Neuropsychopharmacology 2014;24:499-509. [DOI: 10.1016/j.euroneuro.2014.01.014] [PMID: 24491953]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.euroneuro.2014.01.014', 'https://www.ncbi.nlm.nih.gov/pubmed/24491953', 'https://scholar.google.com/scholar_lookup?title=Quality+of+prescribing+for+schizophrenia:+evidence+from+a+national+audit+in+England+and+Wales+&author=MX+Patel&author=D+Bishara&author=S+Jayakumar&author=K+Zalewska&author=D+Shiers&author=MJ+Crawford&publication_year=2014&hl=en']",24491953,https://doi.org/10.1016/j.euroneuro.2014.01.014, Patel 2014 ,additional,CD014383-bbs2-0073,,,,24491953,79,,,24491953
CD014383-bib-0126,"Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. ",Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry, Journal of Clinical Epidemiology ,2008,61,    ,['citation-journal']," Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry.  Journal of Clinical Epidemiology 2008;61(10):991-6. [DOI: 10.1016/j.jclinepi.2007.11.010] [PMID: 18538991]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.jclinepi.2007.11.010', 'https://www.ncbi.nlm.nih.gov/pubmed/18538991', 'https://scholar.google.com/scholar_lookup?title=Contour-enhanced+meta-analysis+funnel+plots+help+distinguish+publication+bias+from+other+causes+of+asymmetry+&author=JL+Peters&author=AJ+Sutton&author=DR+Jones&author=KR+Abrams&author=L+Rushton&publication_year=2008&hl=en']",18538991,https://doi.org/10.1016/j.jclinepi.2007.11.010, Peters 2008 ,additional,CD014383-bbs2-0074,,18538991,18538991,18538991,1703,,,18538991
CD014383-bib-0127,"Popovic D, Benabarre A, Crespo JM, Goikolea JM, González-Pinto A, Gutiérrez-Rojas L, et al. ",Risk factors for suicide in schizophrenia: systematic review and clinical recommendations, Acta Psychiatrica Scandinavica ,2014,130,    ,['citation-journal']," Popovic D, Benabarre A, Crespo JM, Goikolea JM, González-Pinto A, Gutiérrez-Rojas L, et al. Risk factors for suicide in schizophrenia: systematic review and clinical recommendations.  Acta Psychiatrica Scandinavica 2014;130(6):418-26. [DOI: 10.1111/acps.12332] [PMID: 25230813]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/acps.12332', 'https://www.ncbi.nlm.nih.gov/pubmed/25230813', 'https://scholar.google.com/scholar_lookup?title=Risk+factors+for+suicide+in+schizophrenia:+systematic+review+and+clinical+recommendations&author=D+Popovic&author=A+Benabarre&author=JM+Crespo&author=JM+Goikolea&author=A+González-Pinto&author=L+Gutiérrez-Rojas&publication_year=2014&hl=en']",25230813,https://doi.org/10.1111/acps.12332, Popovic 2014 ,additional,CD014383-bbs2-0075,,,,25230813,163,,,25230813
CD014383-bib-0128,,R: a language and environment for statistical computing,,2017,,. Available at www.R-project.org.   ,['citation-other']," R: a language and environment for statistical computing. Version 3.4.2. Vienna, Austria: R Foundation for Statistical Computing, 2017. Available at www.R-project.org.    ",[],,, R [Computer program] ,additional,CD014383-bbs2-0076,,,,,,,,
CD014383-bib-0129,"Ray WA, Chung CP, Murray KT, Hall K, Stein CM. ",Atypical antipsychotic drugs and the risk of sudden cardiac death, New England Journal of Medicine ,2009,360,    ,['citation-journal']," Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death.  New England Journal of Medicine 2009;360(3):225-35. [DOI: 10.1056/NEJMoa0806994] [PMID: 19144938]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1056/NEJMoa0806994', 'https://www.ncbi.nlm.nih.gov/pubmed/19144938', 'https://scholar.google.com/scholar_lookup?title=Atypical+antipsychotic+drugs+and+the+risk+of+sudden+cardiac+death&author=WA+Ray&author=CP+Chung&author=KT+Murray&author=K+Hall&author=CM+Stein&publication_year=2009&hl=en']",19144938,https://doi.org/10.1056/NEJMoa0806994, Ray 2009 ,additional,CD014383-bbs2-0077,,19144938,,19144938,1130,https://www.nejm.org/doi/pdf/10.1056/NEJMx090054?articleTools=true,,19144938
CD014383-bib-0130,,Review Manager Web,,,,". Version 2.4.0. Cochrane, accessed 6 October 2020. Available at revman.cochrane.org/.   ",['citation-other']," Review Manager Web. Version 2.4.0. Cochrane, accessed 6 October 2020. Available at revman.cochrane.org/.    ",[],,, Review Manager Web [Computer program] ,additional,CD014383-bbs2-0078,,41700260,,,,,,41700260
CD014383-bib-0131,"Roberts MT, Shokraneh F, Sun Y, Groom M, Adams CE. ",Classification of psychotherapy interventions for people with schizophrenia: development of the Nottingham Classification of Psychotherapies, Evidence-Based Mental Health ,2021,24,    ,['citation-journal']," Roberts MT, Shokraneh F, Sun Y, Groom M, Adams CE. Classification of psychotherapy interventions for people with schizophrenia: development of the Nottingham Classification of Psychotherapies.  Evidence-Based Mental Health 2021;24:62-9. [DOI: 10.1136/ebmental-2020-300151]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/ebmental-2020-300151', 'https://www.ncbi.nlm.nih.gov/pubmed/33355248', 'https://scholar.google.com/scholar_lookup?title=Classification+of+psychotherapy+interventions+for+people+with+schizophrenia:+development+of+the+Nottingham+Classification+of+Psychotherapies+&author=MT+Roberts&author=F+Shokraneh&author=Y+Sun&author=M+Groom&author=CE+Adams&publication_year=2021&hl=en']",33355248,https://doi.org/10.1136/ebmental-2020-300151, Roberts 2021 ,additional,CD014383-bbs2-0079,,33355248,33355248,33355248,14,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231480,,33355248
CD014383-bib-0132,"Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. ",Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder, Archives of General Psychiatry ,1999,56,    ,['citation-journal']," Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.  Archives of General Psychiatry 1999;56:241-7. [DOI: 10.1001/archpsyc.56.3.241] [PMID: 10078501]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/archpsyc.56.3.241', 'https://www.ncbi.nlm.nih.gov/pubmed/10078501', 'https://scholar.google.com/scholar_lookup?title=Predictors+of+relapse+following+response+from+a+first+episode+of+schizophrenia+or+schizoaffective+disorder+&author=D+Robinson&author=MG+Woerner&author=JM+Alvir&author=R+Bilder&author=R+Goldman&author=S+Geisler&publication_year=1999&hl=en']",10078501,https://doi.org/10.1001/archpsyc.56.3.241, Robinson 1999 ,additional,CD014383-bbs2-0080,,,,10078501,1326,,,10078501
CD014383-bib-0133,"Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, et al. ","Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis", JAMA Psychiatry ,2016,73,    ,['citation-journal']," Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis.  JAMA Psychiatry 2016;73(3):199-210. [DOI: 10.1001/jamapsychiatry.2015.2955] [PMID: 26842482]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/jamapsychiatry.2015.2955', 'https://www.ncbi.nlm.nih.gov/pubmed/26842482', 'https://scholar.google.com/scholar_lookup?title=Efficacy,+acceptability,+and+tolerability+of+antipsychotics+in+treatment-resistant+schizophrenia:+a+network+meta-analysis+&author=MT+Samara&author=M+Dold&author=M+Gianatsi&author=A+Nikolakopoulou&author=B+Helfer&author=G+Salanti&publication_year=2016&hl=en']",26842482,https://doi.org/10.1001/jamapsychiatry.2015.2955, Samara 2016 ,additional,CD014383-bbs2-0081,,,,26842482,286,https://jamanetwork.com/journals/jamapsychiatry/articlepdf/2488040/yoi150088.pdf,,26842482
CD014383-bib-0134,"Samara MT, Nikolakopoulou A, Salanti G, Leucht S. ",How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials, Schizophrenia Bulletin ,2019,45,    ,['citation-journal']," Samara MT, Nikolakopoulou A, Salanti G, Leucht S. How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials.  Schizophrenia Bulletin 2019;45(3):639-46. [DOI: 10.1093/schbul/sby095] [PMID: 29982701]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/schbul/sby095', 'https://www.ncbi.nlm.nih.gov/pubmed/29982701', 'https://scholar.google.com/scholar_lookup?title=How+many+patients+with+schizophrenia+do+not+respond+to+antipsychotic+drugs+in+the+short+term?+An+analysis+based+on+individual+patient+data+from+randomized+controlled+trials+&author=MT+Samara&author=A+Nikolakopoulou&author=G+Salanti&author=S+Leucht&publication_year=2019&hl=en']",29982701,https://doi.org/10.1093/schbul/sby095, Samara 2019 ,additional,CD014383-bbs2-0082,,26842482,,29982701,110,https://academic.oup.com/schizophreniabulletin/article-pdf/45/3/639/28530145/sby095.pdf,,29982701
CD014383-bib-0135,"Shokraneh F, Adams CE. ",Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis, BioImpacts ,2017,7,    ,['citation-journal']," Shokraneh F, Adams CE. Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis.  BioImpacts 2017;7(4):209-17. [DOI: 10.15171/bi.2017.25]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.15171/bi.2017.25', 'https://www.ncbi.nlm.nih.gov/pubmed/29435428', 'https://scholar.google.com/scholar_lookup?title=Study-based+registers+of+randomized+controlled+trials:+starting+a+systematic+review+with+data+extraction+or+meta-analysis+&author=F+Shokraneh&author=CE+Adams&publication_year=2017&hl=en']",29435428,https://doi.org/10.15171/bi.2017.25, Shokraneh 2017 ,additional,CD014383-bbs2-0083,,30863537,,29435428,95,https://bi.tbzmed.ac.ir/PDF/bi-17429,,29435428
CD014383-bib-0136,"Shokraneh F, Adams CE. ",Study-based registers reduce waste in systematic reviewing: discussion and case report, Systematic Reviews ,2019,8,    ,['citation-journal']," Shokraneh F, Adams CE. Study-based registers reduce waste in systematic reviewing: discussion and case report.  Systematic Reviews 2019;8:129. [DOI: 10.1186/s13643-019-1035-3]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/s13643-019-1035-3', 'https://www.ncbi.nlm.nih.gov/pubmed/31146776', 'https://scholar.google.com/scholar_lookup?title=Study-based+registers+reduce+waste+in+systematic+reviewing:+discussion+and+case+report&author=F+Shokraneh&author=CE+Adams&publication_year=2019&hl=en']",31146776,https://doi.org/10.1186/s13643-019-1035-3, Shokraneh 2019 ,additional,CD014383-bbs2-0084,,31146776,31146776,31146776,50,https://systematicreviewsjournal.biomedcentral.com/track/pdf/10.1186/s13643-019-1035-3,,31146776
CD014383-bib-0137,"Shokraneh F, Adams CE. ",Cochrane Schizophrenia Group's Study-Based Register of Randomized Controlled Trials: development and content analysis, Schizophrenia Bulletin Open ,2020,1,    ,['citation-journal']," Shokraneh F, Adams CE. Cochrane Schizophrenia Group's Study-Based Register of Randomized Controlled Trials: development and content analysis.  Schizophrenia Bulletin Open 2020;1:sgaa061. [DOI: 10.1093/schizbullopen/sgaa061]    Link to article     Google Scholar     ","['https://doi.org/10.1093/schizbullopen/sgaa061', ""https://scholar.google.com/scholar_lookup?title=Cochrane+Schizophrenia+Group's+Study-Based+Register+of+Randomized+Controlled+Trials:+development+and+content+analysis+&author=F+Shokraneh&author=CE+Adams&publication_year=2020&hl=en""]",,https://doi.org/10.1093/schizbullopen/sgaa061, Shokraneh 2020 ,additional,CD014383-bbs2-0085,,29435428,,,19,https://academic.oup.com/schizbullopen/advance-article-pdf/doi/10.1093/schizbullopen/sgaa061/34559040/sgaa061.pdf,,29435428
CD014383-bib-0138,"Shokraneh F, Adams CE. ",Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: a study-based analysis, Health Information and Libraries Journal ,,,    ,['citation-journal']," Shokraneh F, Adams CE. Classification of all pharmacological interventions tested in trials relevant to people with schizophrenia: a study-based analysis.  Health Information and Libraries Journal  2021 Feb 18 [Epub ahead of print]. [DOI: 10.1111/hir.12366]    Link to article     ",['https://doi.org/10.1111/hir.12366'],,https://doi.org/10.1111/hir.12366, Shokraneh 2021 ,additional,CD014383-bbs2-0086,,33615663,33615663,33615663,13,https://ora.ox.ac.uk/objects/uuid:25bef0d6-dee7-46d1-bda9-d86e3f3134e4/files/sm613n023q,,33615663
CD014383-bib-0139,"Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. ",RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ ,2019,366,    ,['citation-journal']," Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials.  BMJ 2019;366:l4898. [DOI: 10.1136/bmj.l4898]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.l4898', 'https://www.ncbi.nlm.nih.gov/pubmed/31462531', 'https://scholar.google.com/scholar_lookup?title=RoB+2:+a+revised+tool+for+assessing+risk+of+bias+in+randomised+trials&author=JA+Sterne&author=J+Savović&author=MJ+Page&author=RG+Elbers&author=NS+Blencowe&author=I+Boutron&publication_year=2019&hl=en']",31462531,https://doi.org/10.1136/bmj.l4898, Sterne 2019 ,additional,CD014383-bbs2-0087,,,,31462531,24145,https://www.bmj.com/content/bmj/366/bmj.l4898.full.pdf,,31462531
CD014383-bib-0140,"Tani H, Uchida H, Suzuki T, Fujii Y,  Mimura M. ",Interventions to reduce antipsychotic polypharmacy: a systematic review, Schizophrenia Research ,2013,143,    ,['citation-journal']," Tani H, Uchida H, Suzuki T, Fujii Y,  Mimura M. Interventions to reduce antipsychotic polypharmacy: a systematic review.  Schizophrenia Research 2013;143(1):215-20. [DOI: 10.1016/j.schres.2012.10.015]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.schres.2012.10.015', 'https://www.ncbi.nlm.nih.gov/pubmed/23158205', 'https://scholar.google.com/scholar_lookup?title=Interventions+to+reduce+antipsychotic+polypharmacy:+a+systematic+review&author=H+Tani&author=H+Uchida&author=T+Suzuki&author=Y+Fujii&author=M+\xa0Mimura&publication_year=2013&hl=en']",23158205,https://doi.org/10.1016/j.schres.2012.10.015, Tani 2013 ,additional,CD014383-bbs2-0088,,23158205,,23158205,62,,,23158205
CD014383-bib-0141,"Tanskanen A, Tiihonen J, Taipale H. ",Mortality in schizophrenia: 30-year nationwide follow-up study, Acta Psychiatrica Scandinavica ,2018,138,    ,['citation-journal']," Tanskanen A, Tiihonen J, Taipale H. Mortality in schizophrenia: 30-year nationwide follow-up study.  Acta Psychiatrica Scandinavica 2018;138:492-9. [DOI: 10.1111/acps.12913] [PMID: 29900527]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/acps.12913', 'https://www.ncbi.nlm.nih.gov/pubmed/29900527', 'https://scholar.google.com/scholar_lookup?title=Mortality+in+schizophrenia:+30-year+nationwide+follow-up+study&author=A+Tanskanen&author=J+Tiihonen&author=H+Taipale&publication_year=2018&hl=en']",29900527,https://doi.org/10.1111/acps.12913, Tanskanen 2018 ,additional,CD014383-bbs2-0089,,29900527,29900527,29900527,118,,,29900527
CD014383-bib-0142,"Tiihonen  J, Taipale  H, Mehtälä  J, Vattulainen  P, Correll  CU, Tanskanen  A. ",Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia, JAMA ,2019,76,]   ,['citation-journal']," Tiihonen  J, Taipale  H, Mehtälä  J, Vattulainen  P, Correll  CU, Tanskanen  A. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia.  JAMA 2019;76(5):499-507. [DOI: 10.1001/jamapsychiatry.2018.4320]    ",[],,, Tiihonen 2019 ,additional,CD014383-bbs2-0090,,30785608,30785608,,,,,30785608
CD014383-bib-0143,"Uchida H, Rajji TK, Mulsant BH, Kapur S, Pollock BG, Graff-Guerrero A, et al. ",D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia, Journal of Clinical Psychopharmacology ,2009,29,    ,['citation-journal']," Uchida H, Rajji TK, Mulsant BH, Kapur S, Pollock BG, Graff-Guerrero A, et al. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia.  Journal of Clinical Psychopharmacology 2009;29(6):571-5. [DOI: 10.1097/JCP.0b013e3181bf4ea3] [PMID: 19910723]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1097/JCP.0b013e3181bf4ea3', 'https://www.ncbi.nlm.nih.gov/pubmed/19910723', 'https://scholar.google.com/scholar_lookup?title=D2+receptor+blockade+by+risperidone+correlates+with+attention+deficits+in+late-life+schizophrenia+&author=H+Uchida&author=TK+Rajji&author=BH+Mulsant&author=S+Kapur&author=BG+Pollock&author=A+Graff-Guerrero&publication_year=2009&hl=en']",19910723,https://doi.org/10.1097/JCP.0b013e3181bf4ea3, Uchida 2009 ,additional,CD014383-bbs2-0091,,,19910723,19910723,49,,,19910723
CD014383-bib-0144,"Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG. ",Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review, Health Technology Assessment ,1999,3,    ,['citation-journal']," Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review.  Health Technology Assessment 1999;3(5):iii-92. [PMID: 10982317]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.3310/hta3050', 'https://www.ncbi.nlm.nih.gov/pubmed/10982317', 'https://scholar.google.com/scholar_lookup?title=Methods+for+evaluating+area-wide+and+organisation-based+intervention+in+health+and+health+care:+a+systematic+review+&author=OC+Ukoumunne&author=MC+Gulliford&author=S+Chinn&author=JA+Sterne&author=PG+Burney&publication_year=1999&hl=en']",10982317,https://doi.org/10.3310/hta3050, Ukoumunne 1999 ,additional,CD014383-bbs2-0092,,10982317,,10982317,1057,https://njl-admin.nihr.ac.uk/document/download/2003800,,10982317
CD014383-bib-0145,"van Haren NE, Cahn W, Hulshoff Pol HE, Kahn RS. ",Confounders of excessive brain volume loss in schizophrenia, Neuroscience and Biobehavioral Reviews ,2013,37,    ,['citation-journal']," van Haren NE, Cahn W, Hulshoff Pol HE, Kahn RS. Confounders of excessive brain volume loss in schizophrenia.  Neuroscience and Biobehavioral Reviews 2013;37(10 pt 1):2418-23. [DOI: 10.1016/j.neubiorev.2012.09.006] [PMID: 23000300]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.neubiorev.2012.09.006', 'https://www.ncbi.nlm.nih.gov/pubmed/23000300', 'https://scholar.google.com/scholar_lookup?title=Confounders+of+excessive+brain+volume+loss+in+schizophrenia&author=NE+Haren&author=W+Cahn&author=HE+HulshoffPol&author=RS+Kahn&publication_year=2013&hl=en']",23000300,https://doi.org/10.1016/j.neubiorev.2012.09.006, van Haren 2013 ,additional,CD014383-bbs2-0093,,23000300,,23000300,67,,,23000300
CD014383-bib-0146,"Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. ",Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010, Lancet ,2012,380,    ,['citation-journal']," Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010.  Lancet 2012;380:2163-96. [DOI: 10.1016/S0140-6736(12)61729-2] [PMID: 23245607]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(12)61729-2', 'https://www.ncbi.nlm.nih.gov/pubmed/23245607', 'https://scholar.google.com/scholar_lookup?title=Years+lived+with+disability+(YLDs)+for+1160+sequelae+of+289+diseases+and+injuries+1990–2010:+a+systematic+analysis+for+the+Global+Burden+of+Disease+Study+2010+&author=T+Vos&author=AD+Flaxman&author=M+Naghavi&author=R+Lozano&author=C+Michaud&author=M+Ezzati&publication_year=2012&hl=en']",23245607,https://doi.org/10.1016/S0140-6736(12)61729-2, Vos 2012 ,additional,CD014383-bbs2-0094,,,23245607,23245607,8369,https://europepmc.org/articles/pmc6350784?pdf=render,,23245607
CD014383-bib-0147,Woodhead M. ,"80% of China's clinical trial data are fraudulent, investigation finds", BMJ ,2016,355,    ,['citation-journal']," Woodhead M. 80% of China's clinical trial data are fraudulent, investigation finds.  BMJ 2016;355:i5396. [DOI: 10.1136/bmj.i5396] [PMID: 27707716]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.i5396', 'https://www.ncbi.nlm.nih.gov/pubmed/27707716', ""https://scholar.google.com/scholar_lookup?title=80%+of+China's+clinical+trial+data+are+fraudulent,+investigation+finds&author=M+Woodhead&publication_year=2016&hl=en""]",27707716,https://doi.org/10.1136/bmj.i5396, Woodhead 2016 ,additional,CD014383-bbs2-0095,,27707716,27707716,27707716,57,,,27707716
CD014383-bib-0148,"Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. ",Loss to outcomes stakeholder survey: the LOSS study, Psychiatric Bulletin ,2009,33,    ,['citation-journal']," Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study.  Psychiatric Bulletin 2009;33(7):254-7.    Link to article     Google Scholar     ","['https://doi.org/10.1192/pb.bp.108.021949', 'https://scholar.google.com/scholar_lookup?title=Loss+to+outcomes+stakeholder+survey:+the+LOSS+study&author=J+Xia&author=CE+Adams&author=N+Bhagat&author=V+Bhagat&author=P+Bhoopathi&author=H+El-Sayeh&publication_year=2009&hl=en']",,https://doi.org/10.1192/pb.bp.108.021949, Xia 2009 ,additional,CD014383-bbs2-0096,,,,,297,https://www.cambridge.org/core/services/aop-cambridge-core/content/view/8ECF898917C72AFF772E758874C198B7/S0955603600039623a.pdf/div-class-title-losing-participants-before-the-trial-ends-erodes-credibility-of-findings-div.pdf,,
CD014383-bib-0077,"Shakir M, Van Harten P, Tenback D. ",Concurrent treatment with typical and atypical antipsychotics: double trouble, European Archives of Psychiatry and Clinical Neuroscience ,2017,267,    ,['citation-journal']," Shakir M, Van Harten P, Tenback D. Concurrent treatment with typical and atypical antipsychotics: double trouble.  European Archives of Psychiatry and Clinical Neuroscience 2017;267(1 Suppl 1):S35-6. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Concurrent+treatment+with+typical+and+atypical+antipsychotics:+double+trouble&author=M+Shakir&author=P+VanHarten&author=D+Tenback&publication_year=2017&hl=en']",,, Shakir 2017 {published data only}  ,awaiting_assessment,CD014383-bbs2-0025,,,,,,,,
CD014383-bib-0149,"Bighelli I, Samara MT, Rodolico A, Hansen WP, Leucht S. ",Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia , Cochrane Database of Systematic Reviews ,2021,,    ,['citation-journal']," Bighelli I, Samara MT, Rodolico A, Hansen WP, Leucht S. Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia .  Cochrane Database of Systematic Reviews 2021, Issue 4. Art. No: CD014383. [DOI: 10.1002/14651858.CD014383]    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Antipsychotic+polypharmacy+reduction+versus+polypharmacy+continuation+for+people+with+schizophrenia\xa0+&author=I+Bighelli&author=MT+Samara&author=A+Rodolico&author=WP+Hansen&author=S+Leucht&publication_year=2021&hl=en'],,, Bighelli 2021b ,other_versions,CD014383-bbs2-0097,,36042158,36042158,,,,,36042158
